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ABSTRACT
Twin-screw extrusion, often referred to as Hot-Melt Extrusion within the pharmaceutical
industry, is an efficient, continuous and solvent-free process that has been investigated extensively
for its solubility enhancement applications, and, to a lesser degree, for its potential to replace more
conventional “batch” technologies. The research contained herein focuses on the latter of these
with attention paid to the effects of screw configuration. In this research, the twin-screw extrusion
process was utilized to produce taste masked formulations of a BCS I API, which necessitated the
prevention of amorphous phase formation. The resulting granules were subsequently incorporated
into an immediate release orally disintegrating tablet (ODT) platform. This processing technology
was also evaluated as an alternative platform for the production of dry granulations, henceforth
referred to as Twin-Screw Dry Granulation (TSDG). This novel processing approach was
investigated using Quality by Design (QbD) principles; however, as the QbD paradigm in product
oriented, the process was assessed by the successful production of a drug intermediate and,
ultimately, an optimized target formulation. The TSDG process was utilized to produce a high
drug loaded sustained release solid oral dosage form in which the crystalline lattice was preserved.
Moreover, as a fundamental purpose of granulating technologies is the improvement of the
flowability of one or more of the granule constituents, the resulting granules were assessed for
enhanced flowability when compared to the very poorly flowing API. Finally, the effects of screw
configuration on API morphology was evaluated for the effects of system dependence as the
observed existing literature focuses on single systems wherein the effects of screw configuration
on API morphology are not assessed for their variations from one carrier system to another.
ii

Moreover, the effects of screw configuration were evaluated from the standpoint of the
preservation of the API crystalline lattice as the observed existing information on screw
configuration within the pharmaceutical literature focuses on solubility enhancement via
conversion of the API crystalline lattice into either a molecularly dispersed solid solution or an
amorphous solid dispersion.

iii

DEDICATION
To my parents, Joseph T. Morott, Sr. & Toni S. Sullivan, Ph.D., for not only teaching me the
values of education and hard work, but also for their endless encouragement and support. To my
high school sweetheart and wife, Heather Marie Morott, and my two sons, Alexander Casey
Morott & Kaleb Thomas Morott, you have forfeited far more of my time than could be expected,
so that I could pursue my dream of becoming a credentialed pharmaceutical scientist. I give you
all credit.

iv

ACKNOWLEDGEMENTS
I would like to express my deep and sincere gratitude to my advisor Dr. Michael Andrew
Repka for allowing me to pursue this opportunity at the University of Mississippi. I suspect that I
have learned much more from you than you know. I want to further thank you for all the
opportunities that you afforded me while at Ole Miss, not to mention your enduring patience.
I would like to express sincere appreciation to Dr. John O’Haver. If ever I find myself back
in an academic setting, you are the standard that I will attempt to hold myself to. Our long and
frequent conversations in your office often gave me the encouragement I needed.
To Dr. Soumyajit Majumdar, your continuous positive regard and desire for excellence are
a source of inspiration to the graduate and professional students alike. You may never know how
much your kind words meant to me.
To Dr. Narasimha Murthy, I have met few individuals that are as driven and untiring as
you are. It is truly inspiring seeing how much you accomplish while still making time for the rest
of life. Thank you for granting me patience as both a graduate student and teaching assistant.
In no particular order, I would like to acknowledge my lab mates in the department,
Manjeet Pimprade, Jiannan Lu, Xin Feng, Hemlata Patil, Priyanka Thipsay, Nagendra
Punyamurthula, Anh Vo, and Ketaki Patwardhan thank you for helping to quell the moments of
frustration and doubt with kind conversation. I will miss our reciprocating support.
If I have forgotten to give credit, acknowledgement or appreciation where it is due, I apologize.
There were simply too many names to recall during this exciting, yet hectic, part of my journey.

v

I can only hope to someday inspire others the way that you all have inspired me. Without a single
doubt, these years at the University of Mississippi will remain among my most cherished
memories. For old times’ sake, from the heart, “Hotty Toddy”!

vi

TABLE OF CONTENTS
SECTION

PAGE

Abstract…..…………………………..………………………………………………………..ii
Dedication………………………………………………………………………………..…...iv
Acknowledgements..………………………………………..…………………………………v
List of Abbreviations……………………………………………………………..………….xii
List of Tables…………………………………………...........................................................xv
List of Figures………………………………………………………………………….……xvi
CHAPTER 1: Introduction to Extrusion………………………………………………………1
1.1 Extrusion as a Processing Technology……………………………...…………………1
1.2 Types of Extrusion…………………………………………………………………….1
1.2.1

Ram Extrusion………..……………………………………………………2

1.2.2

Screw Extrusion…………………………………………………………...2

1.2.3

Single Screw Extrusion……………………………………………………3

1.2.4

Twin-Screw Extrusion…………………...…………………….………….7

1.2.5

Pharmaceutical Applications of Hot-Melt Extrusion………….…………...9

CHAPTER 2: The Effects of Screw Configuration and Polymeric Carriers on Hot-Melt
Extruded Taste-Masked Formulations Incorporated into Orally Disintegrating Tablets…....11
2.1 Abstract………………………………………………………………………………11
2.2 Introduction……………………………………………………………………….….12
2.3 Materials and Methods…………………………………………………….……..…..14
vii

2.3.1 Materials……………………………...……………………………………14
2.3.2 Thermogravimetric (TGA) & Differential Scanning Calorimetry (DSC)
Analysis……………………………………………………………………….….15
2.3.3 Hot-Melt Extrusion Processing……………………………..……………...16
2.3.4 Post-Extrusion Drug Content………………………………………………18
2.3.5 High Performance Liquid Chromatography (HPLC) Analysis……………18
2.3.6 Powder X-Ray Diffraction (PXRD) Analysis………….……...…………..18
2.3.7 Fourier Transform Infrared (FTIR) Spectroscopy & Mid Infrared Chemical
Imaging……………………………………………………….…….……………19
2.3.8 Dissolution Testing of Milled Extrudates………………….………………19
2.3.9 Preformulation for Tableting………………………………………………19
2.3.10 Tablet Compression………………………………………………………19
2.3.11 Tablet Properties………………………………………………………….20
2.3.12 Electronic Tongue Analysis……………………………….…………...…21
2.3.13 ODT Oral & Gastric Dissolution…………………………………………21
2.3.14 Physical and Chemical Stability………………………………………….22
2.3.15 Statistical Analysis of Dissolution Data………………………………….22
2.4 Results and Discussion………………………………………………………………23
2.4.1 Hot-Melt Extrusion & Screw Configuration………………………….……23
2.4.2 Thermogravimetric & DSC Analysis………………………………………23
2.4.3 Polymer Screening…………………………………………………………23
viii

2.4.4 PXRD Analysis……………………………………………………….……25
2.4.5 FT-IR & Mid Infrared Chemical Imaging………………………………....27
2.4.6 E-Tongue & Oral Dissolution Testing of Milled Extrudates………………31
2.4.7 Addition of Release Modifying Agents……………………………………33
2.4.8 Tableting API-Excipient Compatibility…….……………………………..35
2.4.9 Tablet Properties………………………………………………….………..36
2.4.10 ODT Oral & Gastric Tablet Dissolution………………………………….38
2.4.11 Physical and Chemical Stability………………………………………….40
2.5 Conclusion…………………………………………………………………………...41
CHAPTER 3: A Quality by Design Investigation of a Novel Twin-Screw Dry Granulation
Process………………………………………………………..……………………………...42
3.1 Introduction…………………………………………………………….…………….42
3.2 Materials and Methods…………………………………………………….…………45
3.3 Methods………………………………………………………………….….………..46
3.3.1 API-Excipient Compatability………………………………….…….……..46
3.3.2 Fourier Transform Infrared Spectroscopy (FT-IR)……………………...…46
3.3.3 Preliminary Range Screening of Formulation and Process Variables….….46
3.3.4 Experimental Design (DoE) & Analysis…….……………………………..47
3.3.5 Physical Mixture Preparation………………………………………………47
3.3.6 Twin-Screw Dry Granulation (TSDG)…………………………………….47
3.3.7 Scanning Electron Microscopy (SEM)…………………………………….48
ix

3.3.8 Dry Granulation Flow Property Measurements……………..…..…………48
3.3.9 Tablet Compression………………………………………………..………49
3.3.10 Tablet Properties…………………………………….……………..……..49
3.3.11 Dissolution Testing………………………………………………..……...50
3.4 Results & Discussion…………………………………………………………..…….50
3.4.1 Preliminary Range Finding Studies & Observations………………………50
3.4.2 Twin-Screw Lubrication…………………………………………...………52
3.4.3 Screw Design………………………………………………………………53
3.4.4 Quality by Design………………………………………………………….55
3.4.5 Experimental Design (DoE) & Analysis…………………………………..55
3.4.6 Main Effects Screening DoE………………………………………………56
3.4.7 Tablet Compression………………………………………………………..57
3.4.8 Tablet Properties…………………………………………………………...57
3.4.9 Characterization DoE………………………………………………………58
3.4.10 Percent Fines……………………………………………………………...60
3.4.11 Hausner Ratio……………………………………………………………..61
3.4.12 Compressibility…………………………………………………………...62
3.4.13 Angle of Repose…………………………………………………………..63
3.4.14 Time to 80% Dissolution…………………………………………………63
3.4.15 Fourier Transform Infrared Spectroscopy (FT-IR)……………………….65
3.4.16 Scanning Electron Microscopy (SEM)…………………………………...66
x

3.4.17 Numeric Prediction of Optimization & Confirmation……….….……….68
3.4.18 Design Space……….……………………………………….……………71
3.5 Conclusion…………………………………………………………………………..72
CHAPTER 4: The Effects of Screw Configuration on API Morphology within Polymeric
Matrices……………………………………………………………….……………………..73
4.1 Introduction……………………………………………………….…………………73
4.2 Materials & Methods……………………………………………….………………..74
4.3 Hot-Melt Extrusion…………………………….…………………….………………74
4.3.1 Thermogravimetric Analysis……..……………………….……………….74
4.3.2 Differential Scanning Calorimetry (DSC)……………………….………...75
4.3.3 Hot-Melt Extrusion Processing…………………………………….………75
4.3.4 FT-IR & Mid-Infrared Chemical Imaging…………………………………75
4.4 Results and Discussion………………………………………………………………76
4.4.1 Thermogravimetric Analysis………………………………………………76
4.4.2 Hot-Melt Extrusion Processing……………………………………………76
4.4.3 FT-IR & Mid-Infrared Chemical Imaging………………………………...76
CHAPTER 5: Summary and Conclusion……………………………………………….…...85
Bibliography…………………………………………………………………….….………..87
Vita………………………………………………………………………………...……………99

xi

LIST OF ABBREVIATIONS
ANOVA…………………………………………………………………...…Analysis of Variance
API…….......................................................................................Active Pharmaceutical Ingredient
ASD………………………………………………………………….Amorphous Solid Dispersion
ATR………………………………………………………………….Attenuated Total Reflectance
BCS……………………………………………………..Biopharmaceutical Classification System
BHT……………………….……………………………………….…...Butylated Hydroxytoluene
CMA………………………..…………………………………………..Critical Material Attribute
CPP……………………………………………………………….....Critical Processing Parameter
CQA…………………………………………………………………..….Critical Quality Attribute
CSD…………………………………………………………………..Crystalline Solid Dispersion
Do……………………….………….……Outer Diameter of Flighted/Conveying Screw Elements
Di………………………….………..……Inner Diameter of Flighted/Conveying Screw Elements
DoE………………………………………………………………………...Design of Experiments
DSC............................................................................................Differential Scanning Calorimetry
EC……………………………………………………………………………….…Ethyl Cellulose
FMEA…………………………………………………………....Failure Mode Effect(s) Analysis
FOV………………………………………………………………………………….Field of View
FPA………………………………………………………………………….…..Focal Plane Array
FTIR…………………………………………………….Fourier Transform Infrared Spectroscopy
HME…………………………………………………………………………...Hot-Melt Extrusion
xii

HPC……………………………………………………………………...Hydroxypropyl Cellulose
HPLC………………………………………………....High Performance Liquid Chromatography
i.e………………………………………………….…………………………………………..id est
L/D……………………………………………………………….……...Length to Diameter Ratio
MIR…………………………………………………………………………………...Mid-Infrared
MSE……………………………………………...………………………….Multi-Screw Extruder
MW………………………………………………………………….…………..Molecular Weight
NCE……………………………………………………………………….…New Chemical Entity
ODT……………………………………………………………….….Orally Disintegrating Tablet
PVP……………………………………………………………………….….Polyvinylpyrrolidone
PXRD…………………………………………………………………..Powder X-Ray Diffraction
QbD……………………………………………………………………………..Quality by Design
QTPP…………………………………………………………….…Quality Target Product Profile
RH………………………………………………………………………………Relative Humidity
RPM……………………………………………………………………….Revolutions per Minute
SC……………………………………………………………………………...…Sildenafil Citrate
SEM………………………………………………………………..Scanning Electron Microscope
SSE…………………………..……………………………………………..Single Screw Extruder
SSF………………………………………………………………………Simulated Salivary Fluid
Tg………………………………………………….………………………………Glass Transition
TGA………………………………………………………………….Thermogravimetric Analysis
xiii

Tm………………………………………………..………………………….Melting Temperature
TSDG……………………………………………………………….Twin-Screw Dry Granulation
TSE………………………………..………………….……………………..Twin-Screw Extruder
USP……………………………..…………………………...………..United States Pharmacopeia
NF……………………………………………………………………………...National Formulary
UV/Vis………………………………………………………...........................Ultra Violet/Visible
VA……………………………...…………………………………………….…..Polyvinyl acetate
XRPD…………………………………………………….…………….X-Ray Powder Diffraction
ZnSe………………………………………………………………………………….Zinc Selenide

xiv

List of Tables
Table………………………………………………………………………………………......Page
2-1: Polymer Screening & Extrusion Parameters………………………………………………..16
2-2: Artificial Salivary Dissolution Media (adjusted to pH 6.8)…………………………...……22
2-3: ODT Formulation Including the Varying Percentages of Super Disintegrant and Filler
Used……………………………………………………………….…………………….……….36
2-4a: ODT Tablet Properties with PVP XL……………………………………….……..………37
2-4b: ODT Tablet Properties with PVP XL-10…………………………………………….……37
3-1: Quality Target Product Profile (QTPP)…………………………………………….…….…45
3-2: Initial Risk Assessment……………………………………………………………….….…55
3-3: Main effects assessed by pareto analysis of screening DoE (Min. Run Res. IV)…….…….57
3-4: Tablet friability and hardness data from the screening DoE with extragranular magnesium
stearate………………………………………………………………………..……..………58
3-5: 23 Full factorial with 4 center points; screw design 1: Figure 2d; screw design 1: Figure
2e…………………………………………………………………………………...…….…59
3-6: Response ranges and statistically significant main effects & interactions from the
characterization DoE………………………………………………………………..………60
3-7: Numerically predicted formulation and process parameters resulting from the input
acceptable ranges on screw design 1; Confirmation: Confirmatory Results…………..……69

xv

List of Figures
Figure………………………………………………………………………………………....Page
1-1: Schematic Representation of a Rudimentary Ram Extrusion Process…………..…………...2
1-2: Schematic Representation of a Single Screw Extruder………………………………………4
1-3: Single Screw Extruder Sections……………………………………………………………...5
1-4: Single Helix Conveying Element…………………………………………………………….6
2-1a-c: Figures 2-1a-1c: Images of the three screw configurations evaluated during HME process
optimization. Figure 2-1a: ThermoFisher “Standard Configuration” 40:1 L/D. Figure 2-1b: All
conveying elements; 40:1 L/D. Figure 2-1c: From Left to Right: 110mm of conveying elements;
22mm of perpendicularly arranged mixing elements; 165mm of conveying elements; 25:1 L/D..17
2-2: SC release profile of preliminary polymer screening formulations in artificial saliva media
adjusted to pH 6.8.……………………………………………………………………….………24
2-3a-b: a; PXRD diffractogram of pure crystalline SC. b; PXRD diffractograms of binary
mixtures of ethylcellulose & SC as a function of screw configurations…………………………26
2-4: FTIR Spectra of Crystalline & Amorphous SC…………………….….….….……………..28
2-5a-c: Chemical image (5.5 µm spatial resolution) of a binary mixture of ethylcellulose & SC
highlighting the intensity of the carbonyl present in crystalline SC processed using screw
configuration 2 (Figure 2-1b). Figure 5b: Chemical image (5.5 µm spatial resolution) of a binary
mixture of ethylcellulose & SC highlighting the intensity of the carbonyl present in crystalline
SC processed using screw configuration 3 (Figure 2-1c). Figure 2-5c: Chemical image (1.1 µm

xvi

spatial resolution) of a binary mixture of ethylcellulose & SC highlighting the intensity of the
carbonyl present in crystalline SC processed using screw configuration 3 (Figure 2-1c).….......30
2-6: Graphical illustration of PCA results from e-tongue analysis illustrating each samples
distance from artificial salivary fluid as a function of screw design. ………………...…………31
2-7: Dissolution data of binary mixtures of ethylcellulose and SC as a function of screw
design…………………………………………………………………………………………….32
2-8: E- Graphical illustration of PCA results from e-tongue analysis illustrating each samples
distance from artificial salivary fluid as a function of individual pore former in each formulation.
………………………………………………………………………….…………………..……34
2-9: Dissolution release profile of milled extrudate (20% SC, 60% ethylcellulose & 20% calcium
carbonate) in artificial salivary media (pH 6.8).………………………………..………....……..35
2-10a: Dissolution profile of optimized SC ODT formulation in artificial salivary fluid (pH
6.8)……………………………………………………………………………………………….39
2-10b: Gastric release profile of optimized SC ODT formulation in gastric media (pH 2)….….39
3-1a-b: (Top) and 3-1b (Bottom): Graphic Illustration of the Observed Differences between a
Polymer Melt on the Mixing Elements (3-1a) and the Compacted Powder Mass Formed During
the TSDG Process (3-1b)……………………….……………………………………………….51
3-2a-e: a: ThermoFisher preconfigured screw design; b: all conveying screw design; c: single
mixing zone screw design; d: two mixing zone screw design; e: modified final mixing zone
screw design………………………………………………………………………………54

xvii

3-3: Percent Fines contour plot and response surface graph with Screw Design 1 (Figure 32b)……………………………………………………………………………………………..…61
3-4: Compressibility contour plot and response surface graph with screw design 1 (Figure 3-2
e)….………………………………………………...……………………………………………62
3-5: Time to 80% Dissolution Contour plot and Response surface graph with Screw Design 1
(Figure 3-2 e)……………………………………………...….………………………………….64
3-6: Mid-Infrared Spectral Evaluation of Sildenafil Citrate’s Post Processing Physical
Phase…………………………………………….………….……….………………………..…66
3-7: A-D: 4A Physical Mixture (100X), 4B Hot-Melt Granule (100X), 4C Dry Granule (100X);
4D Dry Granule (300X)………………………...……………………………………..........68
3-8: Individual independent variable and dependent variable desirability values…….……..…..70
3-9: Desirability function contour plot and corresponding response surface………….…………71
3-10: Overlay plot of the resulting design space…………………………………………………72
4-1: FT-IR spectra of Eudragit E PO (EPO), Carbamezapine (CBZ) and Caffeine Citrate (CC).77
4-2: FT-IR spectral overlay of Eudragit E PO (EPO) and Caffeine Citrate (CC)……………….78
4-3: FT-IR spectral overlay of Eudragit E PO (EPO) and Carbamezapine (CBZ)………………79
4-4: IR chemical images take of CC from the Beginning, Middle and End of Mixing zone…....80
4-5: IR chemical images take of CC from the Beginning, Middle and End of Mixing zone……81
4-6: IR chemical images take of CBZ from the Beginning, Middle and End of Mixing zone….82

xviii

4-7: IR chemical images take of CBZ from the Beginning, Middle and End of Mixing zone…..83

xix

CHAPTER 1.
INTRODUCTION TO EXTRUSION

1.1 Extrusion as a Processing Technology
Extrusion is a commonly utilized processing technology spanning a wide variety of
industries including, but not limited to, ceramics, food, metals, paper, plastics, various chemically
reacted products, and more recently pharmaceuticals [1-10]. In the simplest terms, extrusion is the
process of forcing material through a die into a material of uniform cross-sectional geometry. The
ubiquity of this process is owed, in part, to over 100 years of industrial application, as well as the
numerous variations of the process that are commercially available.

1.2 Types of Extrusion
While it is important to acknowledge the many subclasses of the extrusion process that
exist (e.g. direct, indirect, hydrostatic, sheet, forward, backward, blow film, over jacketing, hot,
cold, etc.), a description and discussion of each is beyond the scope of any single text. Therefore,
as described within this work there are two fundamental sub-classes of this process that are defined
by the method in which the in-process material is moved along the barrel and exits the extruder.
Namely, these are ram extrusion and screw extrusion. While research contained in this work
focuses exclusively on screw extrusion, which can be further subdivided into single and multiscrew processes, a brief description of ram extrusion is provided for completeness.

1

1.2.1 Ram Extrusion
A typical ram type extruder (Figure 1-1) is essentially a piston inside of an extruder barrel
which, in order to accommodate the forward compressive motion of the piston, is necessarily a
complimentary shape, typically a cylinder. The piston, when in its retracted position, allows the
barrel to be filled with the in-process material. In a “hot” process, this material typically remains
within the extruder barrel until achieving a specified temperature and is then compressed by the
piston through the extruder die. In contrast, a “cold” process does not require the material to
achieve a molten state and, as such, is compressed through the die at ambient temperatures.

Figure 1-1, Schematic representation of a rudimentary ram extrusion process

1.2.2 Screw Extrusion
Screw extruders can be divided into three primary subclasses defined as follows:
1. Single-screw Extruders: High pressure systems containing only one screw/auger
within the extruder barrel.
2. Twin-Screw Extruders: Relatively low-pressure systems containing exactly two
screws within the extruder barrel. Often further categorized by the relative direction
2

of rotation (i.e. counter-rotating & co-rotating) and the degree of intermeshing of
the screws within the barrel (i.e. intermeshing & non-intermeshing).
3. Multi-Screw Extruders: Static or rotating center shafts. Further classification can
be more complex and is typically dependent on the number of screws employed.
Regardless of the number of screws employed in the process, there are some commonalities across
the screw extrusion platform. Within each there is a minimum of one screw which is under constant
torque requirements and is responsible for pumping the in-process materials. To achieve this, a
standard assembly consisting of the following basic components, or some variation thereof, is
commonly employed.
1. Motor (drive unit): provides the required torque to the screw(s)
2. Barrel: contains the screws and in-process materials;
3. Die: Attached to the end of the barrel to force the in-process materials into the desired
geometry.

1.2.3 Single Screw Extrusion
Single screw extruders (SSE) were the first type of screw enabled extruders to utilize an
Archimedean type screw for material processing [11]. Single screw extruders are similar in
function to the previously discussed ram extruders with the primary difference being the presence
of a rotating screw within the heated barrel (Figure 1-2). The most notable difference is the
replacement of the ram piston with the continuous rotation of a screw, which provides a clear
avenue for truly continuous processing as the in-process material is not required to remain stagnant
until reaching the desired processing temperature. Instead, the feed material is in constant motion
during the various unit processes (e.g. conveying, plasticizing, melting, devolatization, etc.). The

3

screw’s rotation is powered by a motor, which is typically geared down, thereby reducing the
motor speed to the desired screw speed (rpm). The gearing is usually housed within a box and
surrounded by an oil, which serves to lubricate and cool the gears. Single screw type extruders
function primarily as pumps where the rate of screw rotation provides the forward conveying
capacity of the in-process material(s). In addition to the heated barrel, the shear imparted to the inprocess material from the rotation of the screw within the barrel provides another source of energy
to melt the polymer.

Figure 1-2, Schematic representation of a single screw extruder (SSE) [14].

Owing to the simplicity of their design, they are also the most commonly utilized type of
extruder [12]. This type of extruder employs a single one-piece screw which is continuously
rotated within the extruder barrel. In its simplest form, the screw itself consists of conveying
sections only. However, various alterations have been employed to improve on this basic design
thereby enabling enhanced mixing and distributive properties [13]. A SSE is usually characterized
as a stable high-pressure system capable of consistent output operating in “flood fed” manner
4

whose material throughput determined by the revolutions per minute (rpm) of the screw within the
barrel. It is important to note that a SSE can be operated in a “starve fed” manner, though this
application is less common. In a starve fed mode of operation, the material throughput becomes
less dependent on the screw rpm and becomes almost entirely dependent on the introduction of
new material into the extruder hopper, otherwise referred to as the feed rate.
Multiple unit operations are achieved within the SSE, such as feeding raw material, downstream
conveying or the raw materials or polymer melt, melting of the raw materials, devolatization and
pumping; however, the dispersive and distributive mixing capabilities are generally considered
inferior to that of their multi-screw counterparts.
The screw within a SSE is typically consists of three distinct sections or zones (Figure 13), which can vary in geometry, but are typically defined as Feeding, Transitioning and Metering
The feed section possesses deeper flights to transport the relatively less dense powder material
away from the feed throat to subsequent sections. The transitioning section provides gradual
conversion from the deep flighted feed section, which contains the unmelted pellets or powder, to
the metering section.

Figure 1-3, Single screw extruder (SSE) sections [14].

Additionally, the transition section provides the initial compression of the polymer melt prior to
the metering process. The metering section is the final section in SSE and possesses the shallowest
5

flight depth to facilitate a pressure builds in the polymer melt, which in turn functions to facilitate
extrusion through the die at a consistent rate.
While the ratios of the flight to the root of the SSE screw may vary, it ultimately consists
solely of conveying elements unless otherwise modified. The graphical depiction and
nomenclature of which, is as follows (Figure 1-4):

Figure 1-4, SSE single helix conveying element [14].

•

Channel Depth: The distance from the tip of the flight to the root

•

Channel Width: The distance between successive flights

•

Trailing Flight: Back edge of the flight

•

Pushing Flight: Front edge of the flight

•

Pitch: The distance required for one full 360o rotation of the flight around the screw root

•

Helix Angle: the angle formed between the flight and a line perpendicular, or normal, to
the screw root.

•

Screw Diameter (Do): The distance between the furthest flights on a screw root
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•

Root Diameter (Di): The distance from the channel bottom on one side of the screw to the
channel bottom on the other side of the screw.

•

Do/Di: The ratio of the outer diameter to the inner diameter

The screw itself is typically further characterized by an L/D, or length to diameter ratio. Note that
the length of the screw in Figure 1-3 is taken to be the entire flighted length of the screw, which
typically runs from the base near the feeding section to the tip near the die, and the diameter is
taken to be the screw diameter (Do). The most common ratios used in industry are 25:1 and 40:1,
though others are common as well.

1.2.4 Twin-Screw Extrusion
Twin-screw extruders have two screws placed side by side within the barrel of the extruder.
Functionally, the addition of another screw serves to enhance the compounding ability of the
process, but at the expense of reduced die pressures. In order to take advantage of this enhanced
compounding capacity, the barrel of the extruder is often connected to one or more powder, pellet,
flake, liquid or gas feeding system(s).
With the addition of the second screw within the extruder, a variety of orientations between
the screws became possible. The first distinction to draw is the difference between co-rotating and
counter rotating screws while another distinction is the distance between the screws (i.e.
intermeshing). Co-rotating screw extruder rotate the screws in the same direction, be it either
clockwise or counter clockwise with respect to the vantage point of the observer. Counter rotating
screws rotate in opposing directions, that is, one will rotate clockwise while the other rotates
counter clockwise.
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While extruders with more than two screws are common, it has become apparent that the
twin-screw extruder has become the extruder of choice within the pharmaceutical industry54.
Where single screw extruders typically function as continuous pumps, twin-screw extruders
commonly function as continuous compounders.
For the purposes of this thesis, further conversation will be limited to the fully intermeshing
co-rotating parallel twin-screw extruders, henceforth referred to as a twin-screw extruder, hot-melt
extruder or extruder. This type of extruder has two screws that lie parallel down the length of the
extruder barrel. They are fully intermeshing, which provides a self-wiping mechanism for more
efficient processing and decreased material residence times within the extruder. In order to
facilitate the fully intermeshing corotating mechanics of this process, the additional requirement
that the twin-screws are of identical configurations with an offset about the screw shaft’s axis is
necessitated. Interestingly, this simplifies the process setup.
Where applicable, the extrusion process has numerous inherent advantages over alternative
processing techniques including relative simplicity, economical design, simplicity of scale-up,
small processing foot print, reduced processing time and obvious potential continuous processing.
More recently, this processing technique has been implemented by the pharmaceutical industry.
Although extrusion itself is generally considered to be a unit operation, where extrudates
typically go through further downstream processing, it is most easily viewed as a series of subunit operations. Within the context of twin-screw extrusion, these sub-unit operations are, in
simplest terms, material feeding into the extruder, material conveying and downstream metering,
melting, mixing, venting, and shaping. Feeding solid or liquid raw materials into the extruder is
typically accomplished by either gravimetric (weight loss) or volumetric (volume displacement)
systems.
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1.2.5 Pharmaceutical Applications of Hot-Melt Extrusion
Extrusion has attracted considerable attention in the pharmaceutical industry owing to the
aforementioned reasons. While this process ultimately yields an extrudate of one form or another,
these intermediate extrudate has been utilized to arrive at a wide variety of dosage forms including
tablets, pellets, films, implants and granulations [15-26]. In addition to utilizing extrusion as an
alternative to more conventional technologies present in the pharmaceutical industry, it is also
being investigated for novel processing approaches. Namely, extrusion has been widely explored
as a fusion based technique for arriving at the production of solid dispersions.
The formation of solid dispersions has attracted considerable interest within the
pharmaceutical industry over recent years. This is due, in part, to the nature of many of the new
chemical entities (NCEs) currently under investigation. These NCEs are typically arrived at
through computational chemistry, commonly used to predict the binding affinity of an NCE to a
biological target, or high throughput screening, which utilizes automated processes to assay the
biological activity of numerous compounds over a short period of time. Both approaches tend to
result in compounds that demonstrate exceptional biological characteristics but suffer from poor
aqueous solubility [27-28]. Unfortunately, the lack of aqueous solubility translates into poor
bioavailability, which preempts the successful development of viable drug products [27,28]. To
address the issue of poor aqueous solubility, numerous physicochemical manipulations have been
investigated including nanoparticle formation [29], various salt forms [30,31], co-crystallizations
31,32], pre-solubilized formulations [33-35], and API polymorphisms [35,59]. More recently, the
formation of solid dispersions has attracted substantial attention in both academia and industry.
Solid dispersions were initially described by Chiou & Riegleman as a solid system in which one
or more APIs are dispersed into an inert carrier [36]. The carrier itself can exist in an amorphous,
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crystalline or semi-crystalline (i.e. with both amorphous and crystalline regions) state, while the
API(s) can be in an amorphous, crystalline or molecularly dispersed state within the carrier. Phase
separated dispersions can be further categorized into two subclasses, amorphous and crystalline
dispersions, while the molecularly dispersed API exists as a solid solution. These systems are
commonly differentiated by their respective thermograms, in which, typical phase transition
behavior can be identified. A crystalline solid dispersion would typically exhibit a glass transition
(Tg) for the polymeric carrier and a melting endotherm (TM) for the crystalline API. In contrast, an
amorphous solid dispersion would typically show a glass transition for each of the amorphous
components, both the amorphous/semi-crystalline carrier and the amorphous API. A molecular
level solution would present only a single phase transition for the carrier as the molecularly
dispersed API would not be subject to any phase changes.
There are two broadly cited methods of producing solid dispersions, which are solvent
based systems and fusion based systems. Solvent based methods have historically been utilized to
arrive at solid dispersions due to their simplicity in concept. First, both the carrier and API are
dissolved in a common solvent, which is then followed by solvent removal. The rate of solvent
removal requires consideration with regard to the type of dispersion desired. For example, it is
generally accepted that rapid removal of the solvent tends to result in either a molecular or
amorphous dispersion as the intermolecular forces between API molecules are provided
insufficient time to orient into a crystalline lattice. Lattice formation is further inhibited by the
presence of the polymeric carrier, which functions by interacting with the API via intermolecular
forces, by kinetically hindering the movement of drug molecules, or by a combination of
mechanisms.
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CHAPTER 2.
THE EFFECTS OF SCREW CONFIGURATION AND POLYMERIC CARRIERS ON
HOT-MELT EXTRUDED TASTE-MASKED FORMULATIONS INCORPORATED
INTO ORALLY DISINTEGRATING TABLETS

2.1 Abstract
The primary aim of this research was to produce successfully taste masked formulations of
Sildenafil Citrate (SC) using hot-melt extrusion (HME) technology. Multiple screw configurations
and polymeric carriers were evaluated for their effects on taste masking efficiency, which was
assessed by both E-tongue analysis and in vitro dissolution in simulated salivary fluid (SSF, pH
6.8 artificial saliva). The screw configurations were further assessed for their effects on the
morphology of the API using PXRD, FT-IR and mid-infrared chemical imaging. It was determined
that the screw configuration had a profound effect on the taste masking efficiency of the
formulations as a result of altering the physical state of the API. Selected extruded formulations
using ethylcellulose (EC) with a pore former were further formulated into orally disintegrating
tablets (ODTs), which were optimized by varying the grade and percentage of the
superdisintegrant used. An optimized disintegration time of approximately 8 seconds was
achieved. The final ODT formulation exhibited excellent taste masking properties with over 85%
drug release in gastric media as well as physical tablet properties. Interestingly, friability, which

11

tends to be a common concern when formulating ODTs, was well within the acceptable limits
(<1%) for common tablets.

2.2 Introduction
The perception of taste, or palatability, of a pharmaceutical dosage form is a significant
concern in terms of patient compliance. The development of successfully taste-masked
formulations remains to be a particularly formidable challenge when formulating oral dosage
forms for pediatric populations, who actively refuse to ingest drugs with an unpleasant taste, and/or
geriatric populations, who tend to exhibit unique perceptions of taste [37,38]. A 2003 survey of
Pediatricians conducted by the American Association of Pediatrics concluded that the unpleasant
taste of oral dosage forms was the single greatest obstacle in completing a prescribed therapy due
to a lack of patient compliance [37]. This problem is further accentuated when attempting to
formulate orally dissolving/disintegrating platforms (i.e. dissolvable films, orally disintegrating
tablets, etc.) wherein more traditional methods of taste-masking, such as tablet film coating, are
not feasible. These rapidly dissolving platforms have received considerable attention as they do
not require equipment for dosing (oral syringes, measuring cups, etc.), chewing or additional
liquids in order to be administered. This is because these dosage forms are intended to completely
dissolve or disintegrate utilizing only the saliva available in the oral cavity. While convenient for
all populations, this quality makes them ideal for patients who suffer from dysphagia, which is
common in both pediatric and geriatric populations, where patient compliance is an issue (i.e.
psychiatric disorders, etc.), or for chronic conditions that are characterized by random and rapid
onset such as anxiety attacks or migraine headaches [39-44]. Unfortunately, ODTs tend to be
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relatively fragile and suffer from increased friability which, in turn, leads to more expensive
packaging requirements.
Sildenafil Citrate (SC), a phosphodiesterase type 5 inhibitor with a markedly bitter taste, has
been marketed to both pediatric and geriatric populations as Revatio®, for the treatment of
pulmonary arterial hypertension, and Viagra®, for the treatment of erectile dysfunction,
respectively [45-48]. As a BCS I drug, SC presents an additional difficulty in terms of taste
masking as it readily goes into solution while in the oral cavity thereby allowing it to interact with
taste receptors more rapidly. Moreover, SC is used to treat the aforementioned chronic conditions
which necessitate repeated exposure to the drug and excipients used in these formulations. This is
a particular concern in both pediatric and geriatric populations where a heightened sensitivity to
even the most modest toxicity may exist [49, 50].
Hot-melt extrusion has emerged as a novel and appealing pharmaceutical processing
technology in recent years [51]. HME processes are characterized by the pumping of raw materials
along a rotating screw, or screws, inside a barrel at elevated temperatures. The molten material is
then forced through a die into a substance of uniform shape and character where it is then collected
for further use [52]. HME is an attractive processing option for pharmaceutical applications as it
is a potentially continuous process, does not necessitate the use of water or toxic organic solvents,
is easily scaled up, provides relatively short processing times, and many of the polymeric carriers
employed during processing are generally recognized as safe [52, 53]. This technology is best
recognized for its ability to enhance the solubility of poorly water soluble APIs; however, it can
also be extended to BCS I compounds in which solubility enhancement is not required [54]. This
application is explored in this research through the modification of screw configurations for the
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purpose of maintaining the API’s crystallinity while also achieving acceptable homogeneity in the
extrudates. Here, three configurations and their effects on the physical state of SC are investigated.
To be suitable for taste masking applications, however, the selected polymeric carrier must
have two qualities. First, it must inhibit interaction of the API with taste receptors in the mouth.
Second, it must not appreciably inhibit dissolution in the GI tract. Successful taste masking via
HME technology would minimize both ensuing processing steps as well as the quantity of flavor
enhancing excipients required to produce an acceptably palatable end product. In this current
research, PlasdoneTM S-630 copovidone, AqualonTM N7 ethylcellulose (EC) and multiple grades
of Klucel™ (HF, EF & ELF) hydroxypropylcellulose (HPC) polymers, were evaluated for their
effectiveness in taste masking. The most suitable of the polymeric carriers, ethylcellulose, as
evaluated by taste masking efficiency, was selected for additional experimentation and ultimately
for formulation into an ODT.

2.3 Materials And Methods
2.3.1 Materials
Copovidone (PlasdoneTM S-630), hydroxypropylcellulose (KlucelTM ELF, EF, & HF),
ethylcellulose (AqualonTM N7), PolyplasdoneTM XL & XL-10 and Sildenafil Citrate were kindly
gifted by Ashland Specialty Ingredients (Wilmington, DE). Mannitol (PearlitolTM 300-DC) was
donated by Roquette America Inc. (Keokuk, IA). Sucralose was gifted from JK Sucralose (Jiangsu
Provence, China). Monoammonium Glycyrrhizinate (Magnasweet®) was donated by Mafco
Worldwide CORP. (Camden, NJ). Butylated hydroxytoluene (BHT) was purchased from SigmaAldrich (St. Louis, MO). Magnesium Stearate was purchased from Spectrum Laboratory Products
Inc. (Gardena, CA.). Calcium carbonate, magnesium oxide, calcium chloride dihydrate,
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magnesium chloride hexahydrate, sodium chloride, potassium carbonate, sodium phosphate
dibasic heptahydrate, sodium phosphate monobasic monohydrate as well as all solvents used in
these studies (analytical grade methanol, acetonitrile & water), were purchased from Fisher
Scientific (Norcross, GA). Natural & artificial mint flavoring was gifted by Flavors of North
America (Carol Stream, IL).

2.3.2 Thermogravimetric (TGA) & Differential Scanning Calorimetry (DSC) Analysis
TGA (Pyris 1 TGA Perkin Elmer) was utilized to determine the thermal stability of the
individual polymers, BHT, mannitol, magnesium oxide, calcium carbonate and pure SC. Binary
mixtures (1:1 w/w) of the individual excipients with SC, as well as complete physical mixtures,
were examined at the temperatures required for melt extrusion processing. During TGA, each of
the weighed samples was heated from 25oC to 180oC at a rate of 20oC/min. in a platinum pan under
an inert nitrogen atmosphere purge of 20ml per minute. The samples were held at 180oC for 5
minutes to simulate the thermal stresses encountered during HME.
DSC (Diamond DSC, Perkin Elmer) was utilized to confirm the thermal stability of replicate
TGA samples. The samples, weighing 4-5 mg each, were placed in hermetically sealed aluminum
pans and placed under an inert nitrogen atmosphere at a purge rate of 20ml per minute. These
samples were heated from 25oC to 180oC at a rate of 20oC/min., held at 180oC for 5min. and cooled
to room temperature. The thermograms of the samples were analyzed for deviations from samples
of the pure substances, as well as for other thermal events. Calibration of the instrument was
performed with an Indium reference.
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2.3.3 Hot-Melt Extrusion Processing
Prior to HME processing, the polymers were sieved with a USP #35 mesh screen to remove any
aggregates that may have formed. The compounds necessary for each physical mixture (Table 21) were placed in a V-shell blender (GlobePharma, Maxiblend®) and mixed at 20 rpm for 20
minutes. API content uniformity in the physical mixtures was assessed by HPLC analysis using a
Waters HPLC-UV system (Waters Corp, Milford, MA). A fully intermeshing co-rotating twinscrew extruder (11 mm Process 11TM, ThermoFisher Scientific) was used to process the physical
mixtures. The barrel temperature profile and screw speed were based on the physical properties of
polymeric carrier in each of the preliminary physical mixtures (Table 2-1) and a 3mm rod die was
attached to the end of the barrel. Three screw configurations were investigated for their effects on
the physical state of SC post extrusion (Figure 2-1a-c).

Table 2-1. Polymer screening formulations and extrusion parameters
Drug
Load

Temperature
Range

Screw
Speed
(rpm)

Plasdone ® S-630 copovidone

25%

80-110oC

100

Klucel™ ELF HPC

25%

90-120 oC

100

Klucel™ EF HPC

25%

90-140 oC

100

Klucel™ HF HPC

25%

90-160 oC

100

Aqualon™ N7 EC

25%

90-160 oC

100

Aqualon™ N7 EC

40%

90-160 oC

100

Aqualon™ N7 EC + CaCO3 (20%)

20%

140-160 oC

100

Carrier
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After allowing the extruder to reach a steady state, material was collected from the extruder
as uniform cylindrical extrudates. The extrudates were allowed to cool to ambient temperature and
stored in foil lined polyethylene bags for further processing. The extrudates were later milled using
a comminuting mill (Fitzpatrick, Model L1A). The milled extrudates were sieved to a particles
size range of 300-425µm using what was retained between US #35 and US #40 sieves. The milled
and sieved extrudates were stored in glass vials with a foil lined cap for future use.

Figures 2-1a-1c: Images of the three screw configurations evaluated during HME process
optimization. Figure 2-1a: ThermoFisher “Standard Configuration” 40:1 L/D. Figure 2-1b:
All conveying elements; 40:1 L/D. Figure 2-1c: From Left to Right: 110mm of conveying
elements; 22mm of perpendicularly arranged mixing elements; 165mm of conveying
elements; 25:1 L/D.
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2.3.4 Post-Extrusion Drug Content
A randomly selected portion of each of the extruded formulations was crushed into a fine
powder using a mortar & pestle and analyzed for post-extrusion drug content. A known amount of
the extruded formulations was dissolved in 1:1 methanol:water, diluted with additional 1:1
methanol:water and filtered using 0.2 µm, 13 mm PTFE membrane filters (Whatman, Piscataway,
NJ) and analyzed using HPLC analysis. The same method was used to evaluate the finished ODT
formulations.

2.3.5 High Performance Liquid Chromtography (HPLC) Analysis
The SC content in dissolution samples was analyzed using a Waters (Waters Corporation,
Milford, MA, USA) high performance liquid chromatography (HPLC) system equipped with an
autosampler, UV detector and a Phenomenex® Luna 5µ C18 (150 x 4.6 mm) column. An isocratic
mode of elution with a mobile phase consisting of acetonitrile and water (60:40) at a flow rate of
1.0ml/min. was employed to quantify the drug at a wavelength of 273 nm. The data was acquired
and processed using Waters Empower 3 software suite [55].

2.3.6 Powder X-Ray Diffraction (PXRD) Analysis
Powder X-Ray Diffraction (Bruker AXS, Madison, MI) was utilized to determine the
physical state of SC post extrusion. The X-ray diffraction apparatus used CuKα radiation at 35 mA
and 40 kV, 2°/min, and diffraction angles (2θ) of 5-50.
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2.3.7 Fourier Transform Infrared (FTIR) Spectroscopy & Mid Infrared Chemical Imaging
Mid infrared spectral analysis was conducted on an FT-IR bench (Agilent Technologies
Cary 660, Santa Clara, CA.). The bench was equipped with an ATR (Pike Technologies MIRacle
ATR, Madison, WI), which was fitted with a single bounce diamond coated ZnSe internal
reflection element. Chemical imaging was conducted using an infrared microscope (Agilent
Technologies Cary 620 IR, Santa Clara, CA.) equipped with a 64 x 64 pixel focal plane array
(FPA) with and without a germanium micro-ATR.

2.3.8 Dissolution Testing of Milled Extrudates
The milled and sieved extrudates were tested for in vitro drug release in both 150ml of SSF
(pH 6.8 artificial saliva, Table 2) and 900ml of pH 2 media (0.01N HCl) with USP apparatus I
(Hanson SR8) at 37 ± 0.5°C with a rotation speed of 100 rpm (n=6) [56, 57].

2.3.9 Preformulation for Tableting
Binary (1:1 w/w) mixtures of the milled extrudates with each of the excipients employed
for tableting, as well as complete physical mixtures representative of the final tablet formulations,
were stored under accelerated stability conditions (40°C ± 2°C/75% RH ± 5% RH) for one month.
These samples were then qualitatively analyzed by FT-IR and quantitatively analyzed by HPLC.

2.3.10 Tablet Compression
Prior to direct tablet compression, the milled extrudates were mixed with mannitol,
sucralose and Monoammonium Glycyrrhizinate in a V-shell blender at 20 rpm for 20 min.
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Magnesium Stearate was added during the last 2 minutes of blending. The API content uniformity
was determined by HPLC analysis. ODTs were prepared on a ten-station Piccola tablet press (SMI)
using 8.0 mm standard concave tooling and a compression force of 5.5 kN.

2.3.11 Tablet Properties (Friability, Hardness, Disintegration & Weight Variation)
A dual scooping projection Vanderkamp friabilator (Vankel Industries Inc. Chatham, NJ)
filled with 22 300mg ODTs in one side, to meet USP requirements, was used to assess tablet
friability. The friabilator, which rotates at 25 rpm, was allowed to rotate continuously for four
minutes. The tablets were accurately weighed prior to the test, and carefully de-dusted and
reweighed after the test.
Tablet hardness was assessed using a Schleuniger hardness tester. Each tablet tested was placed
firmly against the stationary anvil prior to beginning the test, and all debris from the previous test
was carefully removed before performing replicate tests (n=10).
Weight variation was measured on a microbalance. 20 tablets were weighed, and their
average determined. The weight of the individual tablets was then compared to the average and
evaluated within USP specified tolerances for uncoated tablets (± 7.5%).
Tablet disintegration time was measured on a disintegration tester (Dr. Schleuniger
Pharmatron). The beakers were filled with one liter simulated salivary fluid (pH 6.8 buffer
solution, Table 2). The unit was thermally equilibrated to 37 ± 2°C (n=6) prior to tablet
disintegration testing. Each tube of the apparatus was used to hold one tablet and each tablet was
covered with a perforated plastic disc. The test was concluded when no particles were retained by
the 10-mesh in the bottom of each tube. Prior to beginning the test, it was determined that the
basket oscillations were between the recommended 28-32 cycles per minute.
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2.3.12 Electronic Tongue Analysis
The electronic tongue samples were assayed on an Astree e-tongue (Alpha M.O.S.) equipped with
sensor set #2 (pharmaceutical analysis) composed of seven sets of sensors (ZZ, AB, BA, BB, CA,
DA, & JE) on a 48 position auto sampler. The individual sample volumes were 25ml and the
acquisition times were set at 120s. The data generated on the e-tongue was analyzed using principle
component analysis on the AlphaSoft V12.3 software suite (Mathworks Inc., Massachusetts,
USA). Each sample was run at least three times, and three replicates of these samples were utilized
for statistical purposes. The sensors and sample containers were thoroughly cleaned with deionized
water between each sample assay. The individual assayed samples were diluted for 60 seconds in
25 ml of phosphate buffer solution (pH 6.8) in order to simulate oral conditions, and the
supernatant liquid was filtered through 2.5 µm syringe filters.

2.3.13 ODT Oral & Gastric Tablet Dissolution
In vitro oral drug release was measured using dissolution apparatus I (Hanson SR8) set to 100 rpm
and equipped with UV-Vis probes (Rainbow Dissolution Monitor, pION) collecting every 5
seconds for 60 seconds at 273nm. The dissolution medium consisted of SSF (150ml of artificial
saliva pH 6.8, Table 2-2) and was maintained at 37 ± 0.5°C (n=6). In vitro gastric release was
evaluated using dissolution apparatus I (Hanson SR8) set to 100 rpm. The dissolution medium
consisted of 0.01N HCl (900ml) and the temperature was held at 37 ± 0.5°C. Samples were
collected at 5, 10, 15 & 30 minute time points (n=6).
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Table 2-2. Artificial saliva dissolution media (adjusted to pH 6.8)
Compounds
Concentration (g/L)
CaCl2·2H2O

0.228

MgCl2·6H2O

0.061

NaCl

1.017

K2CO3·1.5H2O

0.603

Na2HPO4·7H2O

0.204

NaH2PO4·H2O

0.273

2.3.14 Physical and Chemical Stability
The final ODT formulations, as well as milled extrudates containing the API, were stored under
standard (25OC/65% RH) and accelerated (40OC/75% RH) stability conditions for 6 months in
closed glass containers. The dissolution similarity factor (f2) was utilized to compare the poststability dissolution profiles of the ODTs. The milled extrudates were utilized for physical stability
analysis of the API.

2.3.15 Statistical Analysis of Dissolution Data
The dissolution data, whether collected using Uv-Vis probes (section 2.2.12), or more
conventional HPLC analysis (section 2.2.4, 2.2.7 & 2.2.12), were subjected to statistical analysis
using the Similarity Factor (f2) which allows for an accurate comparison of immediate release
dissolution profiles.
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2.4. Results and Discussion
2.4.1 Hot-Melt Extrusion & Screw Configuration Selection
2.4.2 Thermogravimetric & DSC Analysis
Prior to HME processing, an understanding of the thermal behavior of the API and any employed
excipients is critical as thermal degradation of the constituents, or an unexpected chemical reaction
between the constituents, can be thermally induced. The TGA thermograms of the samples were
observed for changes in weight. The thermograms indicated that the drug, excipients and physical
mixtures were chemically stable under the thermal conditions that would be employed for HME
processing as only negligible weight loss near 100oC (<1%), which was attributed to adsorbed
water, was observed. Thermal degradation of SC occurred at approximately 194 oC. DSC data
supported the findings of TGA analysis as no unexpected thermal events were observed under the
same conditions. It was concluded that the temperatures necessary to process the carriers were
suitable to employ. Thermal degradation of SC was observed to occur with the onset of melting at
approximately 194oC. The simultaneous melting and decomposition of SC has been previously
reported and is recognized as thermally induced dissociation of Sildenafil base and citrate wherein
citrate is responsible for the observed degradation [58].

2.4.3 Polymer Screening
Binary Mixtures of the individual polymers with SC were extruded and evaluated for in vitro drug
release in artificial salivary fluid (Figure 2). While each of the polymers that was investigated
showed promising taste masking potential during preliminary screening at up to one minute, the
subsequent accelerated release exhibited by Plasdone S-630 was a source of concern. A
comparison the S-630 dissolution profile with 25% and 40% drug loaded ethylcellulose
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demonstrated a significant difference in terms of similarity factors (f2 = 20 & 36, respectively). It
was, therefore, removed from further consideration. Relative to ethylcellulose, the HPCs (grades
HF, EF and ELF), too, showed a heightened, but steady, release (f2 = 45, 42 & 39, respectively,
when compared to 25% drug loaded ethylcellulose). It was concluded that the initial in vitro drug
release studies of the various carriers indicated that ethylcellulose, with 0.2% BHT as an
antioxidant, provided the greatest taste masking potential and was selected for additional study. A
comparison of two drug loadings (25% & 40%) in ethylcellulose was evaluated (Figure 2-2). At
1.5 minutes of oral dissolution the 40% drug load showed more rapid dissolution (approximately
5%). This finding was not statistically significant when the profiles were compared using the
similarity factor (f2 = 71). The lower drug loading (25% API), which was suitable for the targeted
dose of SC, was selected for additional study.

Drug release in Artificial Saliva at pH 6.8

50%

% Drug Release

40%
75% S-630, 25% Sildenafil
75% EC-N7, 25% Sildenafil

30%

75% HPC HF, 25% Sildenafil
75% HPC EF, 25% Sildenafil

20%

75% HPC ELF, 25% Sildenafil
60% EC-N7, 40% Sildenafil

10%

0%
0

1

2

3

4

5

6

Time (Min.)
Figure 2-2: SC release profile of preliminary polymer screening formulations in artificial
saliva media adjusted to pH 6.8.
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2.4.4 PXRD Analysis
X-Ray diffraction was used to examine the effects of the three screw configurations on the physical
state of SC in the carrier post-extrusion. Figure 3a shows the diffractogram for pure SC for
comparison with the extruded formulations. The effect of the three screw configurations on the
physical state of SC was considerable. The screw configuration in Figure 2-1a (ThermoFisher
Standard Screw configuration; 40:1 L/D) resulted in highly amorphous phase SC, which was both
unnecessary and undesirable in the case of a BCS I API and was, therefore, not utilized for future
processing. The amorphous form, being more readily soluble, would only serve to hinder any taste
masking effects imparted by the carrier. Additionally, the amorphous form of an API is inherently
less thermodynamically stable and, consequently, subject to recrystallization into various
polymorphs, which have differing physical properties, if they exist [59]. This observed conversion
was attributed to not only the length of the screw, and thus increased residence time in the extruder,
but more significantly, the presence of three high shear mixing zones which, depending on
configuration, are primarily responsible for the conversion of crystalline phases of an API to their
morphologically altered, or amorphous, phases [52].
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Figures 2-3a-b: a; PXRD diffractogram of pure crystalline SC. b; PXRD diffractograms of
binary mixtures of ethylcellulose & SC as a function of screw configurations.

The screw configuration in Figure 1b preserved a considerable portion of the crystalline phase
of the API; however, there remained noticeable amorphicity of SC in the carrier as depicted in
Figure 3b. It was speculated that the combination screw length and shear that can occur along the
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flight of conveying elements and the barrel of the extruder was responsible for the amorphicity
noted in the diffractogram. Screw design 3 (Figure 2-1c) was designed to be shorter than the
previous two (25:1 L/D) while still imparting sufficient distributive mixing to the melt. Indeed,
despite the employment of a single mixing section in Figure 1c, in which the mixing elements were
perpendicularly arranged, the diffractogram for screw configuration 3 showed enhanced
preservation of the crystalline structure of SC in the carrier matrix as can be seen in the
diffractogram.

2.4.5 FT-IR & Mid Infrared Chemical Imaging
Mid-infrared (MIR) spectra of crystalline and amorphous SC were collected and compared.
Differences in these MIR infrared spectra allowed for differentiation between the phases in the
extruded material. This was accomplished using a series of spectral derivatives to exploit the
differences highlighted in the spectra (Figure 2-4). It has been previously reported that the unbound
carbonyl, located at 1697cm-1 in the more organized crystalline structure, becomes shifted when it
is free as is the case with Sildenafil base [58].
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Figure 2-4: FTIR spectra of crystalline and amorphous SC.

Additionally, virtually all of the intermolecular bonding is attributed to interaction between COOH
groups in the citrate portion and the carbonyl and the amine group, which appears at 3294cm-1 in
the crystalline form, and is shifted to 3307cm-1 in the amorphous form. The sulfone group, which
appears at 1171cm-1 in the crystalline form has shifted to 1164cm-1 in the amorphous form. In this
study, the amorphous form of SC was produced using the well-known solvent evaporation
technique. The infrared images (Figures 5a-c) were produced by taking spectral derivatives of the
obtained spectra and isolating spectral bands representative of the crystalline phase alone. The
amorphous phase carbonyl center is shifted to 1692cm-1 as opposed to 1697cm-1 in the crystalline
phase.
Figures 2-5a represents an infrared image of crystalline SC in the polymer matrix, post
extrusion using screw configuration 2 (Figure 2-1b), taken at 5.5 µm spatial resolution in
transmission mode with a total field of view (FOV) of 350 x 350 µm. The light blue area represents
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a lack of crystalline API due to either complete absence of SC or the presence of the amorphous
phase. This seems to correspond well with XRD data and analysis of the same material.
Figure 2-5b, representative of screw configuration 3 (Figure 2-1c), illustrates a more uniform
distribution of crystalline SC in the carrier. Here it can be seen that there exists good homogeneity
of SC in the polymeric carrier as indicated by the relatively modest intensity of the carbonyl
centered at 1697 cm-1 that this image is taken with respect to. Additionally, the pockets of
crystallinity are less apparent at this spatial resolution. However, Figure 5c represents an infrared
image taken with a Ge micro ATR at 1.1 µm spatial resolution with a total FOV of 70 x 70 µm.
On closer inspection, it is apparent that there is a slight inhomogeneity of SC in the carrier as the
low intensity blue areas correspond to a complete lack of crystalline SC in that region.
Additionally, the elevated yellow and regions in the images correspond to pockets of crystalline
SC. These small pockets of inhomogeneity are presumably due to preserving the crystalline
structure of SC. Interestingly, this inhomogeneity showed no effect during content uniformity
testing by HPLC analysis and was, therefore, considered negligible. This was presumed to be due
to the small sample size used for the imaging analysis relative to the sample size utilized for HPLC
analysis.
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5a

5b

5c

Figure 2-5a-c: Chemical image (5.5 µm spatial resolution) of a binary mixture of
ethylcellulose & SC highlighting the intensity of the carbonyl present in crystalline SC
processed using screw configuration 2 (Figure 2-1b). Figure 5b: Chemical image (5.5 µm
spatial resolution) of a binary mixture of ethylcellulose & SC highlighting the intensity of the
carbonyl present in crystalline SC processed using screw configuration 3 (Figure 2-1c).
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Figure 2-5c: Chemical image (1.1 µm spatial resolution) of a binary mixture of ethylcellulose
& SC highlighting the intensity of the carbonyl present in crystalline SC processed using
screw configuration 3 (Figure 2-1c).

3.1.5 E-Tongue & Oral Dissolution Testing of Milled Extrudates
Electronic tongue evaluation and in vitro dissolution of the milled extrudates, which consisted of
20% SC loading in ethylcellulose, on the basis of screw configuration supported the physical
characterization studies (FT-IR & XRD). The distance chart (Figure 2-6) graphically illustrates the
principal component analysis results taken as a comparison of the reference or blank (artificial
saliva solution).

Screw Configuration E-Tongue Evaluation Chart
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Figure 2-6: Graphical illustration of PCA results from e-tongue analysis illustrating each
samples distance from artificial salivary fluid as a function of screw design.
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Here it is presumed that the greater the distance to the blank, the less efficient the screw
configuration is for taste masking purposes. It can be seen that pure SC and the physical mixture
are poorly taste masked as they exhibit the greatest distance from the blank, as would be expected.
Screw configuration 1 also produced a poorly taste masked product due to the conversion of the
crystalline lattice of SC to the amorphous form, which goes into solution more rapidly.
Screw configurations 2 & 3 produced comparable results on the basis of e tongue and in vitro
oral dissolution (Figure 2-7); however, the results were not in complete agreement. E-tongue
analysis indicated that screw configuration 3 produced a superior taste masked product, which was
attributed to improved encapsulation of SC in the polymeric carrier. Additionally, FT-IR analysis
indicated that the crystalline lattice was more effectively preserved when employing this
configuration, which further explains the differences in e-tongue analysis. On the other hand, the
dissolution data indicated screw configuration 2 produced a slightly better product in terms of taste
masking.

In Vitro Release in Artificial Saliva (pH 6.8)
Percent Drug Release
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Figure 2-7: Dissolution data of binary mixtures of ethylcellulose and SC as a function of
screw design.
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Upon closer examination of the dissolution profiles for these screw configurations at 30
seconds, which is the maximum amount of time the formulation is expected to remain in the oral
cavity, there exists a negligible difference (<1%) between the two profiles, which was further
supported by the similarity factor comparison (f2 = 73). These observations along with the physical
characterization data, wherein it was shown that screw configuration 3 produced a more uniform
crystalline dispersion, aided in deciding that screw configuration 3 would be utilized for further
processing. Interestingly, there seems to exist a strong correlation between the e-tongue analysis,
wherein greater distance would be indicative of greater interaction of the API with the taste
sensors, and dissolution data, which indicates the amount of API in solution available for the
perception of taste.

2.4.7 Addition of Release Modifying Agents
While ethylcellulose, an erodible polymer, was selected due to a very low release profile in
artificial saliva, it became necessary to incorporate a release modifying agent for more rapid drug
diffusion as gastric drug release was correspondingly low. Magnesium oxide and calcium
carbonate were selected as potential pore formers due to being practically insoluble near salivary
pH while being completely soluble at or near gastric pH. Mannitol was also used as a pH
independent pore former. Additionally, it was postulated that any dissolution of mannitol in the
oral cavity could have potentially served as an additional taste masking agent as a result of being
a sugar alcohol with a sweet flavor.
Initial e-tongue screening of the individual pore formers within the extruded matrices (20% each)
demonstrated promising results (Figure 2-8) for both magnesium oxide and calcium carbonate.
However, magnesium oxide produced highly erratic results during gastric dissolution screening
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and was therefore removed from consideration for further taste masking application. Based on the
distance chart results for the pore formers, mannitol was also excluded from further consideration.
It was observed that the quantity of mannitol needed for adequate pore forming capacity was
assisting in solubilizing SC during the melt extrusion processing, which hindered the taste masking
capacity of the formulations. This observation explains why mannitol ranked very closely to pure
SC during the e-tongue analysis.
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Figure 2-8: Graphical illustration of PCA results from e-tongue analysis illustrating each
samples distance from artificial salivary fluid as a function of individual pore former in each
formulation.

Oral dissolution data for calcium carbonate agreed well with the e-tongue results (Figure 29) without producing the unpredictable results associated with magnesium oxide. These data were
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as hypothesized as calcium carbonate is insoluble near neutral pH, which should prevent the
formation of diffusion promoting pores, thus keeping the exterior of the matrix intact. Because of
these observations, calcium carbonate as the pore former was selected for additional studies.

In vitro Oral Release With CaCO3 in
Artificial Saliva (pH 6.8)
Percent API Dissolved
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Figure 2-9: Dissolution release profile of milled extrudate (20% SC, 60% ethylcellulose &
20% calcium carbonate) in artificial salivary media (pH 6.8).

2.4.8 Tableting API-Excipient Compatibility
After storage for one month under accelerated stability conditions (40oC/75% RH), HPLC analysis
was conducted to evaluate the compatibility of the extruded formulations with the excipients
selected for direct compression tableting (Table 2-3). All API-excipient compatibility samples
were dried in the presence of desiccant prior to investigation in order to remove adsorbed water
which would interfere with both qualitative spectral analysis and quantitative chromatographic
data analysis. API-excipient compatibility studies were evaluated qualitatively by FTIR analysis
35

wherein the spectra were observed for the appearance and/or disappearance of previously
unobserved characteristics. When no changes in the infrared spectra were observed, these samples
were further evaluated quantitatively using HPLC analysis. No incompatibilities were noted.

Table 2-3. ODT formulation including the varying percentages of super disintegrant and
filler used
Constituents

Concentration

PVP (Grades XL & XL-10)

2.5, 5 & 10%

Sucralose

1%

Magnasweet

1%

Nat. & Art. Mint Flavor

1%

Milled Extrudate

41.7% (Equivalent to 25mg of SC)

Mannitol (300DC)

52.3, 49.8 & 44.8%

Magnesium Stearate

0.5%

2.4.9 Tablet Properties
Tablets containing varying levels of super disintegrant (PVP XL & XL-10) were evaluated for
common tablet properties (Tables 4a & 4b respectively). The percentage of super disintegrant
evaluated ranged from 2.5-10. As noted earlier, friability tends to be a common concern when
formulating ODT platforms. To the contrary, these formulations exhibited excellent friability (0.80.32) despite having somewhat low hardness values (2.68-6.56 kp). The low hardness values are
attributed to the poor compressibility and high loading (41.7%) of the milled extrudates in the
ODT formulations. Interestingly, the disintegration times for the ODTs were within the acceptable
limits for ODT designation (approximately 8-33 seconds depending on formulation), which are
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generally taken to be less than 30 seconds. While the tablets formulated with PVP XL-10
demonstrated improved hardness and friability values, those formulated with PVP XL
demonstrated superior disintegration times, which is a primary concern when formulating rapidly
dissolving platforms. Remarkably, tablets containing 5.0% PVP XL had average disintegration
times of 8.6 seconds. With the other properties within the acceptable ranges, priority was given to
disintegration time. Therefore, ODTs containing 5.0% PVP XL were selected for oral and gastric
dissolution studies.

Table 2-4(a). Tablet properties as a function of the percentage of PVP XL incorporated
2.5% PVP XL
5.0% PVP XL
10% PVP XL
Disintegration Time (sec.)

11.3±1.01

8.6±0.62

9.3±1.63

Percent Friability

0.24±0.01

0.32±0.02

0.19±0.01

Thickness (mm)

4.63±0.06

4.63±0.05

4.67±0.01

Hardness (kp)

3.57±0.64

2.67±0.30

2.89±0.55

Loss on Drying (w/w)

2.22±0.46

2.37±0.42

2.66±0.63

Table 2-4(b). Tablet properties as a function of the percentage of PVP XL 10 incorporated
2.5% PVP XL-10
5.0% PVP XL-10
10% PVP XL-10
Disintegration Time (sec.)

33.3±5.10

27.7±2.71

30.0±3.99

Percent Friability

0.08±0.02

0.23±0.001

0.13±0.01

Thickness (mm)

4.64±0.02

4.63±0.09

4.66±0.14

Hardness (kp)

6.56±0.50

5.68±0.31

5.90±0.48

Loss on Drying (w/w)

2.17±3.00

2.34±0.20

2.61±0.52

2.4.10 ODT Oral & Gastric Tablet Dissolution
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Oral and gastric dissolution profiles (Figures 2-10a-b) were evaluated for finished product (ODT
containing 5% PVP XL) drug release. While the oral dissolution study was conducted for 60
seconds, a disintegration time of approximately 8 seconds indicates that the formulation would
remain in the oral cavity for 30 seconds or less. At this time, the tablets exhibited a mere 2% drug
release. The gastric release profile of the tablets indicates that excellent release can be obtained by
incorporating the milled extrudates into rapidly dissolving platforms. In this case, more than 80%
drug release was realized with 60 minutes.
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Figure 2-10a: Dissolution profile of optimized SC ODT formulation in artificial salivary
fluid (pH 6.8)
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Figure 2-10b: Gastric release profile of optimized SC ODT formulation in gastric media (pH
2).
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2.4.11 Physical and Chemical Stability
The milled extrudates were assessed for physical stability of the API by both FT-IR and PXRD
analysis. There was no observable difference in the spectra generated by either method indicating
that that the specific polymorphic crystalline lattice had been preserved after both standard and
accelerated stability testing, as would be expected. The milled extrudates were also assessed for
chemical stability by HPLC analysis using the method outline in section 2.2.4, and their similarity
factor was calculated (f2 = 89).
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4. CONCLUSION
In this study, HME was successfully employed as a processing technology for the production of
taste masked formulations containing SC. This was accomplished by embedding the API in
ethylcellulose along with a pH dependent pore former. The crystallinity of SC, and presumably
the subsequent physical stability, was found to be dependent on the screw configuration and pore
former used. FT-IR spectroscopic imaging, in tandem with conventional XRD analysis, proved to
be very valuable in the evaluation of the melt-extruded formulations as it was demonstrated that
preserving the crystalline structure of SC was critical for arriving at successfully taste masked
formulations. The addition of calcium carbonate into the extruded formulations proved to be
especially advantageous in that its pH dependent solubility helped prevent drug dissolution under
oral conditions (pH 6.8) while promoting drug dissolution under gastric conditions (pH 2). The
ODT formulations demonstrated uncharacteristic but excellent friability profiles without
sacrificing disintegration time, which is critical for ODT formulations. E-tongue assessment of
taste masking efficiency, in conjunction with dissolution data, was found to be extremely valuable
and mutually supportive.
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CHAPTER 3.
A QUALITY BY DESIGN INVESTIGATION OF A NOVEL TWIN-SCREW DRY
GARANULATION PROCESS
3.1 Introduction
Historically, extrusion processes have found considerable applicability in a multitude of
processing fields. A few examples might include metal & plastic profile extrusion, ceramic
extrusion, cooking & confectionary extrusion, plastic & rubber compounding extrusion, polymer
synthesis reaction extrusion, and finally, with over a century of industrial refinement,
pharmaceutical extrusion [1-11]. The extrusion processing platform, be it ram, single or multiscrew, has a sound reputation for being economical, efficient, continuous and, most importantly,
consistently reliable for the repeated production of high quality products. The later of these
qualities, being a source of ill repute and vulnerability for the pharmaceutical industry as evidenced
by the ubiquity of drug recalls, has led to the FDA’s substantial push for QbD guided process
development [60, 61]. While most of the primary requirements for developing a QbD based process
are conceptual in nature (QTPP, FMEA, DoE), and thus easily implemented in a wide array of
processes, those required by the enhanced QbD requirements, namely in-line process monitoring
and process controls, are relatively foreign to conventional pharmaceutical processing
technologies. By contrast, these in-process analytics and controls are not only integrated into
extrusion systems, but are also fundamental to the process.
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Twin-screw extrusion has attracted considerable attention in the pharmaceutical industry as an
alternative processing technology where bioavailability enhancement is required and multiple
review articles cover this application aspect in detail [62-65]. More recently, the innumerable
advantages inherent to extrusion processing (economical processing, small scale-up footprint,
reduced in-process times, solvent free/green processing, reduced processing steps, continuous
processing, etc.) have led to applicability studies where solubility enhancement is either not
required, undesirable or where this processing technology simply imparts its advantages over more
conventional processing platforms. Indeed, investigations in twin-screw granulation processes are
rapidly increasing, and for good reason [66-83].

With approximately 70 percent of

pharmaceuticals being solid dosage forms, and the primary physical modification of the bulk
ingredients being a granulation process of one form or another, any advancement in granulation
technology is going to have significant implications [84].
Granulation processes are commonly employed in the pharmaceutical industry as a means to
increase particle size, reduce segregation, improve flowability and enhance compressibility. Dry
granulations are often considered useful for formulations that have acceptable compression
properties, but suffer from poor flowability. Unlike wet granulations, dry granulations do not
require the formation of a wet mass along with the subsequently necessary drying operations, and
are also suitable for hydrolysable compounds. Typically, a dry granulation process consists of the
addition of mechanical energy to a formulation containing a dry binder. The resulting
agglomerated mass is then often subjected to one or more milling, sieving and blending operations.
The primary objective of this work was to investigate the previously unreported utility of
a fully intermeshing, co-rotating, twin-screw extruder for the development of a Twin-Screw Dry
Granulation (TSDG) process. TSDG fundamentally differs from the more conventional
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pharmaceutical applications of twin-screw extruders (i.e. Hot-Melt Extrusion; HME) in that the
formulation’s constituents are not processed into a continuous melt within the barrel, but are
instead compacted into discrete agglomerates. In further contrast to HME processes, wherein the
in-process melt functions as the lubricant for the barrel and rotating screws, an additional powder
lubricant was required to prevent the observed metal on metal contact during TSDG processing.
The TSDG process differs substantially from its wet granulation counterpart as well in that no
solvents or binder solutions are required. This is particularly advantageous in that the need for
subsequent, and often lengthy, drying operations is circumvented along with analytical
determinations of residual organic solvents when used. Moreover, this dry processing approach
does not preclude the incorporation of hydrolytically sensitive actives or excipients. Careful
attention to screw design was required as there existed a balance between simply pushing the
powdered formulation through the extruder (powder in-powder out), the formation of melted
material and the formation of a dry granulated material.
A Quality by Design approach was implemented in order to arrive at a well-defined process
yielding a product of predefined character and quality. In this case study, Sildenafil Citrate, a BCS
class I API, was utilized as a model drug for the granulating process. The selection of this API was
beneficial in that it exhibits poor flowability, which makes it ideal for a granulating process
wherein high drug loading is desired. Additionally, a BCS I API poses the possible challenge of
undesirable amorphous phase formation, an application for which twin-screw extruder processing
is both well-known and suited.
The objectives outlined in the quality target product profile (QTPP) were to produce a high
drug loaded, sustained release formulation in which the API’s pre-existing crystalline lattice was
preserved (Table 1). The resulting granules were assessed for surface morphology, API phase

44

changes, chemical interactions, conventional granule properties (i.e. compressibility index, angle
of repose, Hausner ratio), and finally utilized to produce a high drug loaded sustained release solid
oral dosage form.

Table 3-1: Quality Target Product Profile (QTPP)
QTPP Element

Target

Justification

Dosage form

Tablet

Route of administration

Oral

Pharmaceutical equivalence requirement:
same dosage form
Pharmaceutical equivalence requirement:
same route of administration

Dosage strength

100 mg

Pharmacokinetics

In vitro dissolution – 12-18hrs
80% release

Stability

At least 6 months 40C/75RH
accelerated stability

Drug Product quality
attributes

Physical Attributes

Tablets (size, color, shape)

Identification

Positive identification for sildenafil citrate

Assay

90.0-110.0 (Compendial requirement)

Content Uniformity

AV < 15.0 (USP<905>)

Degradation Products

Monitor and report (CQA)

DSC

Monitor and report (CQA)

TGA

Monitor and report (CQA)

XRPD

Monitor and report (CQA)

NIR

Monitor and report (CQA)

Residual Solvents

Will not be monitored for this study
Extended Release

Drug Release

Container Closure System
Administration/concurrence
with labeling
Alternate methods of
administration

Will not be monitored for this study
Will not be monitored for this study

Microbial Limits
Water Content
NA
NA
NA

3.2 Materials & Methods
Hydroxyethyl cellulose (NatrasolTM 250 L), ethyl cellulose (AqualonTM N7), hydroxypropyl
cellulose (KlucelTM HF) and Sildenafil Citrate were generously donated by Ashland Specialty
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Ingredients (Wilmington, DE). Magnesium Stearate, hydrochloric acid and the solvents used in
this study (analytical grade methanol & water), were purchased from Fisher Scientific (Norcross,
GA).

3.3 Methods
3.3.1 API-Excipient Compatibility
Binary (1:1 w/w) mixtures of the API with each of the excipients, as well as complete physical
mixtures representative of the final tablet formulations, were stored under accelerated stability
conditions (40°C ± 2°C/75% RH ± 5% RH) for one month. These samples were then analyzed by
FT-IR spectroscopy.

3.3.2 Fourier Transform Infrared Spectroscopy (FT-IR)
Mid infrared spectral collection was performed on an FT-IR bench (Agilent Technologies Cary
660, Santa Clara, CA.). The bench was equipped with an ATR (Pike Technologies MIRacle ATR,
Madison, WI), which was fitted with a single bounce diamond coated ZnSe internal reflection
element. The spectra were collected over a range of 4000-650cm-1. Spectral analysis was
conducted using the Resolutions Pro software suite (Agilent Technologies, CA.).

3.3.3 Preliminary Range Screening of Formulation & Process Variables
Prior to a formal DoE, preliminary studies were conducted to evaluate acceptable process
parameter ranges (e.g. screw configurations, screw speeds, feed rates, etc.) and formulation
variables (e.g. polymer ratios, inter/extra-granular lubricant, API morphology, etc.).
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3.3.4 Experimental Designs (DoE) & Analysis
Experimental designs were created and evaluated using DoE software (StatEase, Design-Expert®
Version 8.0.6, Minneapolis, MN). A fractional factorial design (Min Run Res IV) with two center
points was used as a screening design for the elucidation of main effects, which resulted in a total
of 16 experimental runs. A full factorial 2 level (23) with four center points was utilized to evaluate
interactions between the previously selected main effects and curvature present within the design.
The full factorial design necessitated an additional 12 experimental runs. Finally, the results from
the full factorial design were used to produce contour plots, response surface plots, and to predict
an optimized formulation and process.

3.3.5 Physical Mixture Preparation
Prior to TSDG processing, the polymers were sieved using a USP #35 (500 µm) mesh screen to
remove any aggregates that may have formed. The components necessary for each physical
mixture were geometrically diluted using a glass mortar and pestle.

3.3.6 Twin-Screw Dry Granulation (TSDG)
A fully intermeshing, co-rotating, twin-screw extruder (11mm Process 11TM, ThermoFisher
Scientific) was used to process the physical mixtures. The extruder experiments were conducted
without a die on the extruder barrel. After allowing the extruder to reach a steady state, material
was collected from the extruder in the form of granules and/or fine powder. The granules were
stored in polyethylene bags for further processing and/or analysis.
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3.3.7 Scanning Electron Microscopy (SEM)
SEM was used to assess the surface morphology of the final optimized formulation in three
different forms. These were the physical mixture, a representative melt extruded sample, and the
optimized dry granulated sample. Prior to sample mounting, the surfaces of the samples was cut
with a razor in order to provide a flat surface to focus upon. Adhesive carbon tape was used to
mount the samples onto an aluminum stage. These samples were then sputter coated with gold
under an argon atmosphere using a Hummer 6.2 Sputter Coater (Ladd Research Industries,
Williston, VT, US). The coater was kept under a high-vacuum evaporator equipped with an omnirotary stage tray to help ensure uniform coating. Finally, the images were captured using a JSM5600 scanning electron microscope (JEOL USA, Inc., Waterford, VA, US) at an accelerating
voltage of 5 kV. The samples were evaluated at multiple magnifications.

3.3.8 Dry Granulation Flow Property Measurements
The powder/granulation flow peoperties were measured and assessed in accord with the current
USP-NF37 guidelines. The bulk volume (Vo) of 25 g of granules was measured in 50 ml of
graduated glass cylinder. The bulk density (ρb) was calculated using the following equation:
Bulk density (𝜌𝑏 ) =

amount of granules weighed (25 g)
bulk volume (𝑉𝑜 )

The graduated glass cylinder was tapped 100 times and the reduced volume of the granules was
measured. Tapped density (ρt) was calculated by using the volume of the granules after tapping
100 times (Vf) using the following equation:
Tapped density (𝜌𝑡 ) =

weight of granulation/powder (25 g)
tapped volume (𝑉𝑓 )
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Carr’s (compressibility) index (CI) and Hauser’s ratio (HR) were calculated using the following
equations:
CI =

(𝜌𝑡 − 𝜌𝑏 )
× 100
𝜌𝑡

𝐻𝑅 =

𝜌𝑡
𝜌𝑏

The angle of repose was measured using a funnel method outlined in the USP-NF37. The height of
the funnel was placed above the horizontal surface such that the upper tip of the resulting cone
lightly touched the tip of the funnel. The weighed granules were poured freely through the funnel
onto the horizontal base. The diameter and the height of the cone was measured and the angle of
repose (θ) was calculated by the following equation, where ‘h’ and ‘r’ are the height and radius of
the formed cone, respectively:
𝑇𝑎𝑛 (𝜃) =

ℎ
𝑟

3.3.9 Tablet Compression
The tablets were prepared on a single station tablet press (Globe) using 8.0 mm flat face tooling
and standard concave tooling. The compression force varied per the experimental design
requirements in the screening study, which were evaluated at 100, 200 & 300 kg/cm2 in the main
effects screening study. Compression forces greater than 300 kg/cm2 resulted in formulation
leakage around the compression tooling. The compression force was held constant in the
optimization study (200 kg/cm2).

3.3.10 Tablet Properties
A dual scooping projection Vanderkamp friabilator (Vankel Industries Inc. Chatham, NJ) filled
with 33 200mg tablets in one side, to meet USP requirements, was used to assess tablet friability.
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The friabilator was allowed to rotate continuously for four minutes at 25rpm. The tablets were
accurately weighed prior to the test, and carefully de-dusted and reweighed after the test.
Tablet hardness was assessed using a Schleuniger hardness tester. Each tablet tested was placed
firmly against the stationary anvil prior to beginning the test, and all debris from the previous test
was carefully removed before performing replicate tests (n=10).
Weight variation was measured on a microbalance. Twenty tablets were weighed, and their
average determined. The weight of the individual tablets was then compared to the average and
evaluated within USP specified tolerances for uncoated tablets (± 7.5%).

3.3.11 Dissolution Testing
The tableted formulations were assessed for in vitro drug release in 900ml gastric media (0.01N
HCl) using USP apparatus I (Hanson SR8) at 37 ± 0.5°C with a basket rotation speed of 100 rpm
over a 24 hour period. The dissolution vessels were equipped with UV-Vis fiber optic probes
(Rainbow Dissolution Monitor, pION) and the detector was set at a wavelength (λMax) of 290nm.

3.4 Results & Discussion:
3.4.1 Preliminary Range Finding Studies & Observations
Prior to utilizing a statistical experimental design, it was necessary to conduct a series of
prescreening and range finding studies as no prior knowledge was available to suggest appropriate
formulation and/or operational parameters for this novel process. As would be anticipated,
observations that are unique to this dry granulating approach were made.
Figures 3-1a & 3-1b below provide a visual comparison of the in-process materials, and illustrate
the observed differences between the formation of a typical polymer melt, depicted in Figure 3-
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1a, and a compacted dry mass, Figure 3-1b, of the same composition. It should be noted that
presence of mixing elements was necessary to provide the compaction forces which resulted in the
formation of the dry granules. As can be seen in Figure 3-1b, uncompacted powder is metered out
by the conveying elements and subsequently compacted by the mixing elements, where the
compact takes on the matte appearance similar to that of a roller compacted ribbon. Discrete
granules (Figure 3-1b) can be seen along the conveying elements moving beyond this compaction
zone and toward the discharge elements of the screws.

Figure 3-1a (Top) and 3-1b (Bottom): Graphic Illustration of the Observed Differences
between a Polymer Melt on the Mixing Elements (3-1a) and the Compacted Powder Mass
Formed During the TSDG Process (3-1b).
Additionally, the ability to easily mill the compact back into a fine powder further indicates that a
dry agglomerate is being formed. In contrast, the material on the mixing zone in Figure 3-1a has
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the glossy appearance that commonly results from the complete melting of polymers. The melted
mass could not be easily removed, nor crushed back into a fine powder. This is a common
occurence during HME processes as pharmaceutical polymers tend to have a relatively high
affinity for metal after achieving a molten state.
During processing, it was consistently observed that dry powder exited the barrel prior to
the appearance of granules, indicating that a buildup of back pressure was required to facilitate the
agglomeration process. This differs from HME processes in that, while the generation of back
pressure is common with extruders in general, during a melt extrusion or melt granulation process
agglomerated material typically appears immediately when output is achieved. Additionally, the
torque values measured during a melt extrusion process tend to become elevated at steady state as
the polymeric carriers become molten and viscous. On the other hand, during the TSDG process
the torque values remained exceptionally low with relatively large fluctuations ranging from 0.723.12 Nm. This observation was brought to greater acuity when the optimized formulation was both
dry granulated and melt extruded with the barrel temperature profile being the only adjusted
variable. The polymer melt produced consistent torque values of approximately 5.3 Nm. While
seemingly low, the torque values resulting from the melt process are also a function of the reduced
feed rate, which were representative of the feed rate employed during the TSDG process.

3.4.2 Twin-Screw Lubrication
During a melt extrusion process, the melt itself serves as the lubricant for the moving parts during
processing; however, during a TSDG process this is not the case as no melted material is present.
During these preliminary studies, observable metal-on-metal contact between the extruder screws
and barrel frequently occurred. In order to prevent product degradation and/or contamination, as
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well as damage to the processing equipment itself, it became desirable to incorporate a solid
lubricant. Similar concerns are commonly addressed during tableting processes by the addition of
nominal quantities of a solid lubricant such as magnesium stearate or stearic acid. Likewise, the
addition of magnesium stearate was investigated for the mitigation of these effects. While the
addition of modest quantities of magnesium stearate (0.2%) eliminated the previously observed
metal-on-metal noises emanating from the extruder, it was observed that a narrow range of its
utility existed as the addition of relatively larger quantities (0.5%) resulted in unfavorable
quantities of fine particles (often greater than 50%). This was attributed to excessive lubrication
of the powder mass by the magnesium stearate, which, in turn, resulted in decreased compactability
of the dry mass within the extruder. The addition of even larger quantities (1.0%) frequently
prevented the formation of granules entirely. Likewise, the method of its addition also produced
varying effects on the granulating process. More specifically, the addition of magnesium stearate
into the physical mixture needed to occur during the final stage of blending as earlier addition
would also prevent granulation. Finally, limiting the quantity of dry lubricant present while
granulating, and the utter absence of a lubricating melt, required limiting the extruder’s screw
speed to a maximum of 200 rpm.

3.4.3 Screw Design
Screw configuration demonstrated profound effects on the process. Figure 3-2a-e illustrates the
various screw configurations explored during this research. Figure 3-2a shows a configuration that
is similar to those used in typical polymer processing or HME operations as the numerous mixing
elements impart considerable shear to the in-process materials. This configuration consistently
resulted in the formation of a melt material at any appreciable screw speed. On the other hand, the

53

screw design in Figure 3-2b, which consisted of all conveying elements, served to merely pump
the powdered material through the extruder’s barrel.

Figure 3-2a-e: a: ThermoFisher Preconfigured Screw Design; b: All Conveying Screw
Design; c: Single Mixing Zone Screw Design; d: Two Mixing Zone Screw Design; e:
Modified Final Mixing Zone Screw Design.
Beginning again with configuration 3-2b, three mixing paddles were added near the discharging
end of the barrel, which resulted in a third configuration (Figure 3-2c). This configuration was
capable of yielding granules. From this observation, it was apparent that an alternative approach
to screw configuration, relative to HME applications, was required to produce a dry granulation.
Two additional configurations capable of producing granules were developed (Figures 3-2d & 32e). In Figure 3-2d, an additional mixing zone has been added closer to the feeding hopper. The
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configuration in 3-2e is a modified version of 3-2d where the mixing elements near the discharge
section of the screw has been altered in order to evaluate effects of mixing element offset angle.

3.4.4 Quality by Design
In general, QbD studies involve the systematic utilization of various elements and tools (e.g.
QTPP, Risk Assessment, DoE, etc.). This phase of investigation began with the identification of
the product’s critical quality attributes (CQAs) in the quality target product profile (QTPP, Table
1). Based on the predefined CQAs, excipients possessing the critical material attributes (CMAs)
were selected. In the same fashion, the critical processing parameters were identified and selected
for further study. Based on these observations, an initial risk assessment (Table 3-2) was performed
to openly identify the variables perceived to pose that greatest risk to the CQAs. The CMAs &
CPPs (inputs) were statistically analyzed through the DoE process where variation therein was
assessed for variations in the CQAs (outputs).

Table 3-2: Initial Risk Assessment
Process steps
Drug Product CQAs
Size
Assay
Content Uniformity
Drug Release

Twin Screw
Granulation
Low
High
Low
High

Milling

Compression

Low
Low
High
High

Low
Low
High
High

3.4.5 Experimental Designs (DoE) & Analysis
Prior to implementing the DoE, multiple factors were fixed. For example, the percent of intragranular magnesium stearate used to lubricate the powder mixture, as well as the screws, was held
at constant at 0.2% during the compaction process, while extra-granular magnesium stearate was
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held constant at 0.5% for compression purposes. Additionally, it had been previously observed
that variation in tablet tooling (standard concave vs. flat face) produced no observable variations
in the tablets physical properties (disintegration, hardness & friability). This was attributed to the
relatively large quantities of binder in the formulations. All of the polymers that were evaluated
(ethyl cellulose, hydroxypropyl cellulose & hydroxyethyl cellulose) were capable of producing
granules using the process and formulation ranges that were employed; however, in order to reduce
the number of experiments required by a DoE, the subsequent experiments were limited polymeric
blends consisting of HPC and HEC only.

3.4.6 Main Effects Screening DoE
A fractional factorial design (Minimum Number of Runs with Resolution IV; Min Run Res IV)
with two center points was utilized as a screening design in order to determine the main effects
from the formulation and process variables. The ranges of the responses and their main effects are
listed in Table 3-3. Crystallinity, hardness and friability were not evaluated during the
optimization/characterization phase of the DoE as they consistently produced acceptable values
within the ranges under investigation. Additionally, these ranges would only be further restricted,
rather than broadened, in subsequent studies.

\
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Table 3-3 Main effects assessed by pareto analysis of screening DoE (Min. Run Res. IV).
Response

Range

Main Effect

Crystallinity

NA

NA (Always Maintained)

Percent Fines

12 – 49%

Hausner Ratio

1.05 – 1.39

Screw Configuration

Compressibility Index

4.76 – 28.17

Screw Configuration

Angle of Repose

22.0 – 38.7

Polymer Ratio

Tablet Friability

0.0 0.3%

Drug Loading

Tablet Hardness

8.6 – 18.7kp

Polymer Ratio

Screw Config., Compression
Force, Drug Loading
Time to 80% Dissolution

3.0 – 15.3 hr.

Polymer Ratio, Drug Loading

3.4.7 Tablet Compression
Initially, tablets were compressed without the addition of extra-granular excipients; however, this
resulted in the occasionally observed picking and sticking (the adherence of granulated particles
to the tablet tooling) upon tablet ejection. The addition of 0.5% extra-granular magnesium stearate
prevented these previously observed failures.

3.4.8 Tablet Properties
The granules produced in the initial screening design were mixed with and additional 0.5% extragranular magnesium stearate and pressed into tablets using the appropriate compression force and
the same 8mm flat face tooling. These reformulated tablets were assessed for hardness and
friability (Table 3-4).
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Table 3-4. Tablet Friability and Hardness Data from the Screening DoE with
extragranular magnesium stearate.
Run Order Friability (%) Hardness (kp)
1
0.05
15.8
2
0.18
16.0
3
0.10
15.9
4
0.10
18.7
5
0.0
11.5
6
0.05
12.6
7
0.15
14.0
8
0.30
8.6
9
0.10
13.6
10
0.05
11.2
11
0.0
12.1
12
0.0
11.8
13
0.0
15.0
14
0.05
17.3
15
0.05
13.4
16
0.15
14.4

3.4.9 Characterization DoE
With the completed main effects/screening design results, which reduced the previously
investigated six independent variables to three main effects (i.e. screw design, polymer ratio &
drug loading), a full factorial (23) with four center points (Table 3-5) was created to evaluate
potential interactions between the main effects, and, ultimately, to predict an optimized
formulation and process.
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Table 3-5: 23 Full Factorial with 4 Center Points. Screw Design 1: Figure 2d; Screw Design
2: Figure 2e.
Run
Screw
Polymer
Drug
Fines
Hausner Compressibility 80%
Design
Ratio
Loading
(%)
Index
Disso.
(HPC:HEC)
(%)
(hr.)
1
1
3:1
50
13.2
1.3
24.4
12.5
2
2
1.7:1
42.5
14.0
1.3
25.4
11.5
3
2
3:1
35
10.5
1.3
22.4
15
4
2
1:1
35
13.6
1.2
13.5
11.5
5
1
1.7:1
42.5
13.1
1.3
20.5
14
6
1
1.7:1
42.5
10.3
1.3
24.4
12
7
1
1:1
50
17.1
1.3
23.1
8.5
8
2
1.7:1
42.5
13.2
1.3
24.4
12
9
2
1:1
50
10.7
1.3
20.3
6.5
10
1
3:1
35
10.7
1.2
15.6
15
11
2
3:1
50
12.6
1.2
19.2
11
12
1
1:1
35
11.0
1.3
22.5
8

The parameters that did not produce main effects in the screening design (i.e. screw-speed, feed
rate & tablet compression force) were presumed to have ngelible effects relative to the main effects
and, as such, the mean of their previously utilized ranges was taken and implemented in the
characterization study at fixed values. Therefore, the extruder’s feeder output was set to 4g/min
(previous range: 3-5g/min.), the screw speed was maintained at 150rpm (previous range: 100-200
rpm), and the tablet compression force was held constant at 200kg/cm2 (previous range: 100-300
kg/cm2) . The barrel temperature was held at 65oC from zones 2 until granule discharge. The
responses, their statistically significant main effects and interactions are summarized in Table 3-6
and further discussed in the ensuing individual sections.
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Table 3-6: Response Ranges and Statistically Significant Main Effects & Interactions from
the Characterization DoE.
Response
Range
Interaction Type and/or Main Effect(s)
Polymer Ratio & Drug Loading (Main Effects);
Percent Fines
10.3 – 17.1
Interaction with Screw Design
Screw-Configuration, Polymer Ratio & Drug
Hausner Ratio
1.2 – 1.3
Loading (3-Way Interaction)
Compressibility
Polymer Ratio & Screw Configuration (Main Effects
13.5 – 25.4
Index
& Two Way Interaction)
Angle of Repose
33.7 – 42.0
Insufficient Variation Within the Model
Time to 80%
Polymer Ratio & Drug Loading (Independent Main
6.5 - 15
Dissolution (hr.)
Effects; Interaction with Screw Configuration)

3.4.10 Percent Fines
The following values were used in the analysis of variance (ANOVA) of the “percent fines”
response variable. A Model F value of 14.64 in the unadjusted model suggests that the model is
significant. The “Lack of Fit F-Value” 0.75 indicates that the lack of fit is not significant (p >
0.0011). The model is statisitically significant for the response Percent Fines with an “R-Squared”
value of 0.7262. The Predicted R-Squared value (0.430) is in reasonable agreement with the
Adjusted R-Squared value (0.5698). The adequacy/precision ratio of 7.697 indicates an adequate
signal. This model can be used to navigate the design space. The following polynomial equation,
which is expressed in terms of coded factors, was generated for the mathematical description of
percent fines generated during granulation: Percent Fines = +12.49 -0.67*B –0.98*C -1.18*A*C;
where A, B and C are the screw configuration, polymer ratio and drug loaing respectively. In this
equation, a positive or negative sign prior to a coded variables coefficient is inversely related to an
additive or deleterious effect respectively as the response variable is a measure in increasing inprocess fine material. In this case, an decrease in the polymer ratio, which corresponds to a
decrease in the high molecular weight binder (HPC HF), corresponds to a increase in fine material,
where an increase in drug content corresponds to decrease in fine materials. The above equation is
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graphically depicted by both a contour plot and response surface for a visual assessment of these
variables (Figure 3-3).

Figure 3-3: Percent Fines contour plot and response surface graph with Screw Design 1
(Figure 3-2 d).

3.4.11 Hausner Ratio
The Hausner Ratio of the granules was evaluated using the procedure outlined by the USPNF37. The full factorial experiments resulted in the range of values of 1.16 – 1.34, which, while
satisfying the compendial specifications spanning “Good” to “Passable”, did not produce sufficient
variation to result in a predictive model (Model F value 1.13, Predicted R2 -2.27). Given these
results, the values for the Hausner ratio were not used to produce a predictive equation. Instead,
given that the entire range of values was acceptable, the span of the data points was taken and
utilized to inform numerically predicted solution.
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3.4.12 Compressibility
The following values were used in the analysis of variance (ANOVA) of the “compressability”
response variable. A Model F value of 7.24 in the unadjusted model suggests that the model is
significant. The “Lack of Fit F-Value” 0.70 indicates that the lack of fit is not significant (p >
0.01114). The model is statisitically significant for the response Percent Fines with an “R-Squared”
value of 0.7308. The Predicted R-Squared value (0.4679) is in reasonable agreement with the
Adjusted R-Squared value (0.6299). The adequacy/precision ratio of 6.545 indicates an adequate
signal. This model can be used to navigate the design space. The following polynomial equation,
which is expressed in terms of coded factors, was generated for the mathematical description of
compressability of the granulation: Compressability = +22.08 +1.25*A –1.50*B +0.5*C 1.50*AB; where A, B and C are the screw configuration and polymer ratio and drug loaing
respectively.

Figure 3-4: Compressibility contour plot and response surface graph with screw design 1
(Figure 3-2 e).
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3.4.13 Angle of Repose
The flowability of the granules was evaluated using the Recommended Procedure for Angle of
Repose outlined by the USP-NF [86]. The full factorial experiments resulted in the range of values
presented in (33.7 – 42.0), which produced insufficient variation to result in a sufficiently
predictive model. However, this range of values falls within the qualitatively described ranges for
angle of repose in the USP-NF [86]. More specifically, the range presented spans what the USP
describes as “Good” to “Fair”. Given these results, the values for the angle of repose were not used
to produce a predictive equation. Instead, given that the entire range of values was acceptable, the
mean of the data points was taken and utilized to inform numerically predicted solution.

3.4.14 Time to 80% Dissolution
The in-vitro drug release was assessed using the conditions outlined for this drug by the FDA [87].
The following values were used in the analysis of variance (ANOVA) of the dissolution predictive
model. A Model F value of 14.67 in the unadjusted model suggests that the model is significant.
The “Lack of Fit F-Value” 2.20 indicates that the lack of fit is not significant (p > 0.0011). The
model is statisitically significant for the response Time to 80% Dissolution with an “R-Squared”
value of 0.7653. The Predicted R-Squared value (0.5668) is in reasonable agreement with the
Adjusted R-Squared value (0.7131). The adequacy/precision ratio of 10.468 indicates an adequate
signal. This model can be used to navigate the design space. The following polynomial equation,
which is expressed int terms of coded factors, was generated for the mathematical description of
tablet dissolution: Time to 80% Dissolution = +11.46 +2.37*B –1.38*C; where B and C are the
polymer ratio and drug loaing respectively. In this equation, a positive or negative sign prior to a
coded variables coefficient is indicative of an additive or deleterious effect respectively. In this
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case, an increase in the polymer ratio, which represents and increase in the high molecular weight
polymer (HPC HF), corresponds to prolonging dissolution. Likewise, a decrease in drug content
also corresponds to an increase the time it takes to reach 80% dissolution. As might be anticipated
when employing a high molecular weight polymer and a BCS I API, an increase in the amount of
the high molecular weight polymer was correlated with an increase in dissolution time (indicated
by the “+” symbol in the equation), while an increase in drug loading was correlated with a
decrease in dissolution time (indicated by the “–“ symbol in the equation). This equation is
graphically depicted by both a contour plot and response surface for a visual assessment of these
variables (Figure 3-5).

Figure 3-5: Time to 80% Dissolution Contour plot and Response surface graph with Screw
Design 1 (Figure 3-2 e)

As might be anticipated when employing a high molecular weight polymer and a BCS I API, an
increase in the amount of the high molecular weight polymer was correlated with an increase in
dissolution time (indicated by the “+” symbol in the equation), while an increase in drug loading
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was correlated with a decrease in dissolution time (indicated by the “–“ symbol in the equation).
This equation is graphically depicted by both a contour plot and response surface for a visual
assessment of these variables (Figure 3-5).

3.4.15 Fourier Transform Infrared Spectroscopy (FT-IR)
FT-IR spectral analysis (Figure 3) clearly illustrates the differences between the crystalline and
amorphous phases of Sildenafil Citrate. As would be expected, the amorphous phase exhibits
shifted, shorter and broader spectral bands relative to the crystalline phase. These alterations in
spectral responses arise from the lack of long range order that is characteristic of the amorphous
phase. This allows for the identification of the API’s post-processing physical phase, which
demonstrates that the API is still crystalline. Interestingly, the physical mixture shows the carbonyl
in Sildenafil Citrate, which is centered at 1697cm-1, in the same position as the carbonyl in the
pure crystalline spectrum, whereas the dry granulated carbonyl is centered at 1699cm -1. While
there is obviously a spectral shift occurring, it is shifted in the opposite direction of the carbonyl
in the amorphous phase. This may be indicative of hydrogen bonding between the carbonyl in
crystalline Sildenafil Citrate and the hydroxyls (ranging from approximately 3600-3200cm-1)
present in the polymeric carrier(s), which, considering their relative proportions within the
mixture, may be assisting in the formation of the granules.
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Figure 3-6: Mid-Infrared Spectral Evaluation of Sildenafil Citrate’s Post Processing
Physical
Phase.

3.4.16 Scanning Electron Microscopy (SEM)
Figure 3-7a through 3-7d illustrates the visually observable differences in the surface morphology
between the physical mixture, the dry granules and the hot-melt granules, respectively. These
samples are representative of the optimized formulation predicted by the full factorial model. In
Figure 3-7a it can be observed that the dry granulated material appears to be a compacted
agglomerate of the physical mixture presented in Figure 3-7b. The image of the Hot-Melt
Granulated material in Figure 3-7c appears homogenous and lacks the observable appearance of
its constituents. Further magnification of the Hot-Melt Granulated material revealed no additional
information; however, Figure 3-7d, taken at 300X magnification, demonstrates that compacted
agglomeration of the primary particles is still apparent in smaller domains.
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Figure 3-7A-D: 4A Physical Mixture (100X), 4B Hot-Melt Granule (100X), 4C Dry
Granule (100X); 4D Dry Granule (300X).

3.4.17 Numeric Prediction of Optimization & Confirmation
The full factorial model was used to predict a set of graphically and numerically optimized
formulations (Table 3-7). The criteria for the optimization process were based on the CQAs in the
QTPP as well as the acceptable ranges for the measured responses found in the USP. With a
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relatively broad range of acceptability for the dissolution profile (80% in 12 – 18 hrs.), the target
was set to the median value (15 hrs.). The percentage of fines was set to a range of 10 – 15%, as
this is the generally acceptable . The lower limit of the Hausner Ratio was set to the lowest value
obtained during this study (1.15) and the upper limit was set to 1.25 as the USP defines this as the
cutoff “Fair” flowability. The range for the angle of repose was set such that it encompassed the
lowest value attained in this study
Of the most desirable predicted solutions to the predefined ranges and targets, solution 1 was
selected as it incorporated the highest drug loading, which was one of the primary objectives of
this research, and it possessed the most favorable desirability value (0.558). The predicted values
of the proposed formulation and process were then compared to the measured values in during
confirmation stage of optimization. The measured values are presented in Table 3-7.

Table 3-7: Numerically predicted formulation and process parameters resulting from the
input acceptable ranges on screw design 1; Confirmation: Confirmatory Results from
Prediction Number 1.
Predicted
Solution
Number

Polymer
Ratio

Drug
Load
(%)

Percen
t Fines

Hausner
Index

Compress.
Index

Time to
80% Disso.

Angle
of
Repose

Desirability

1

3:1

42.7

11.85

1.25

19.70

13.82

39

0.558

2

3:1

42.6

11.82

1.25

19.63

13.84

39

0.552

Confirmation

3:1

42.7

12.05

1.22

21.1

14

36

NA

Based on the desired input model criteria for the individual independent and dependent variables,
the resulting individual desirability values are graphically depicted in Figure 3-8. While the criteria
for both the independent variable “drug loading” and the dependent variable dissolution were each
given the highest priority of the model variables, which are consistent with the product criteria
established in the QTPP, it can be seen that their respective desirability values lie well below that
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of the other responses. This is clearly explained by the inversive relationship between the two
variables, that is, the time required to reach 80% dissolution decreases as drug loading increases
and vice versa, and equal priority having been given to both. As such, a balance, or compromise,
between the two criteria was established by the resulting model.
The overall desirability contour plot and response surface (Figure 3-9) was for predicted
solution 1 (Table 3-7) was constructed to graphically depict the complete relationship between the
independent variables and predefined and prioritized response value ranges. Addtionally, these
plots serve to illustrate that an optimal region of overlap is predicted to exist. It is important to
note that while the range for desirability is predefined from 0.0 – 1.0, that the obtained value
(0.558) is a multiplicative mean rather than additive mean, which is to say that if any value were
unable to meet the input specifications, the desirability function would become 0.0. Therefore, it
is the existence of some appreciable value greater than 0.0 that is of importance here, which
justifies proceeding with predicted solution confirmatory experiment (Table 3-7).

Figure 3-8: Individual independent variable and dependent variable desirability values.
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Figure 3-9: Desirability function contour plot and corresponding response surface.

3.4.18 Design Space
When attempting to optimize for multiple variables, it is necessary to find the region where all
requirements are met simultaneously. The close agreement of the Predicted Solution values with
the values collected from the confirmation experiment (Table 3-7) suggest the suitability of the
predictive model. As such, the previous contour plots (Figures 3-3, 3-4 & 3-5) have been
superimposed to produce the overlay plot in Figure 3-10. This overlay is representative of what is
considered to be the design space, shaded in blue, where the control space being chosen a subset
thereof. It can be seen from the plot that the most limiting of the response (dependent) variables
were the lower boundry condition set for percent fines (10 -15%) and the upper boundry condition
set for Hausner’s Ratio (1.34). The compressibility index and angle of repose, within the ranges
studied in this factorial design, did not impose on the design space whatsoever.
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Figure 3-10: Overlay plot of the resulting design space.

3.5 Conclusion
This study explores the previously unreported applicability of a fully intermeshing co-rotating
twin-screw extruder for the production of dry granules. Fundamental differences from
conventional HME processing were discovered and assessed accordingly. Screw design played an
integral role in the formation of the granules, while the extruder feed rate was limited by the
absence of a lubricating polymer melt. Utilizing the QbD methodology to investigate this
alternative dry granulation process facilitated rapid and efficient method development.
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CHAPTER 4.
THE EFFECT OF MIXING BLOCK OFFSET ANGLE ON THE DISTRIBUTION OF
CARBAMEZAPINE AND CAFFEINE CITRATE IN A POLYMERIC MATRIX
4.1 Introduction
While screw configuration is widely regarded as a critical processing parameter in extrusion
processes, as it plays a vital role in the physicochemical characteristics of the final extrudates, little
practical information is available in the literature concerning the effects of screw configuration on
pharmaceutical formulations. Moreover, nearly all of that information is focused on the conversion
of a crystalline API into its amorphous form with little attention given to the intermediate changes
that occur during processing. To some extent this stands to reason as the initial obstacles that HME
was investigated to address were related to the poor aqueous solubility of many newer APIs.
However, given the numerous processing advanteges that this platform offers, it is well poised to
serve as an alternative to many more conventional pharmaceutical processing technologies.
Moreover, this particular platform readily embraces the agency’s current thinking on
pharmaceutical regualtory matters; namely continuous processing. Given some of the additional
advantages inherent in HME processing (i.e. , fewer processing steps, simple scalability, avoidance
of organic solvents, etc.), it becomes apparent that processing any suitable API by this technique
is an attractive option regardless of which BCS class it belongs to. However, in the case of BCS
class I and class III APIs, where the formation of an API’s amorphous phase might not be desirable,
it may be appropriate to preserve the initial crystalline structure as solubility enhancement is not
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necessary and common stability issues associated with amorphous forms, such as recrystallization
into an undesired polymorphic form, can be avoided. Conversely, a complete understanding of the
morphological changes that are induced in such an environment poses the possibility controlled
conversion between polymorphs in situ, much like conversion from a crystalline lattice to a
molecular or amorphous dispersion is peformed today. The objective of this study is to evaluate
the effects of screw configuration on active pharmaceutical ingredient (API) morphology using a
fully intermeshing co-rotating twin-screw extruder and FT-IR chemical imaging for spatial
determinations. Here the examination takes place within the mixing zones along the co-rotating
screw.

4.2 Materials & Methods
Eudragit E PO was generously donated by Evonik (Somerset, NJ.). Carbamezapine and Caffeine
Citrate were donated by Ashland Specialty Ingredients (Wilmington, DE).

4.3 Hot-Melt Extrusion
4.3.1 Thermo Gravimetric Analysis (TGA)
Prior to melt extrusion processing, TGA (Pyris 1 TGA Perkin Elmer) was utilized to determine the
thermal stability of the individual polymers and API. Binary mixtures (1:1 w/w) of the individual
polymers with the API were examined at the temperatures required for melt extrusion processing.
During TGA, each of the weighed samples was heated from 25oC to 180oC at a rate of 20oC/min.
in a platinum pan under an inert nitrogen atmosphere purge of 20ml per minute. The samples were
held at 180oC for 5 minutes to simulate the thermal stresses and residence time encountered during
HME processing.
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4.3.2 Differential Scanning Calorimetry (DSC)
DSC (Diamond DSC, Perkin Elmer) was utilized to confirm the thermal stability of replicate TGA
samples. The samples, weighing 4-5 mg each, were placed in hermetically sealed aluminum pans
and placed under an inert nitrogen atmosphere at a purge rate of 20ml per minute. These samples
were heated from 25oC to 180oC at a rate of 20oC/min., held at 180oC for 5min. and cooled to room
temperature. The thermograms of these samples were analyzed for deviations from the
thermograms of the pure substance and other significant thermal events. Calibration of the
instrument was performed with an Indium reference.

4.3.3 Hot-Melt Extrusion Processing
Prior to HME processing, the polymer was sieved with a USP #35 mesh screen to remove any
aggregated particles. The compounds required for each physical mixture were placed in a V-shell
blender (GlobePharma, Maxiblend®) and mixed at 20 rpm for 20 minutes. A fully intermeshing
co-rotating twin-screw extruder (11 mm Process 11, ThermoFisher Scientific) was used to process
the physical mixtures.

4.3.4 FT-IR & Mid-Infrared Chemical Imaging
Mid-infrared spectral analysis was conducted on an FT-IR bench (Agilent Technologies Cary 660,
Santa Clara, CA.). The bench was equipped with an ATR (Pike Technologies MIRacle ATR,
Madison, WI), which was fitted with a single bounce diamond coated ZnSe internal reflection
element. Chemical imaging was conducted using an infrared microscope (Agilent Technologies
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Cary 620 IR, Santa Clara, CA.) equipped with a 64 x 64 pixel focal plane array (FPA) with a
germanium micro-ATR.

4.4 Results and Dsicussion
4.4.1 Thermogravimetric Analysis
No thermal events were noted during thermogravimetric analysis of the binary mixtures during
the course of this study, which is indicative of thermal stability over the temperature ranges
utilized.
4.4.2 Hot-Melt Extrusion Processing
The barrel temperature profile and screw speed were based on the physical properties of polymeric
carrier in each of the preliminary physical mixtures and a 2mm rod die was attached to the end of
the barrel. After allowing the extruder to reach a steady state, a barrel plug was removed from the
top half of the barrel, which exposed the respective mixing zones, and samples were collected
directly from the mixing elements for analysis. The samples were either immediately analyzed, or
stored in foil lined polyethylene bags for future analysis. Three screw configurations. Each screw
design was characterized by three consecutive mixing blocks. Each block was composed of mixing
paddles with offset angles of 30o or 90o each. It is important to note that these angles were not
investigated in conjunction with eachother, but were examined for the individual angle effects on
the dispersion and distribution each active (CC or CBZ) within the EPO matrix.
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4.4.3 FT-IR & Mid-Infrared Chemical Imaging
A qualitative examination of the FTIR spectrum for each of compounds indicates that there
exists a region of clear spectral resolution for each of the model drugs within the polymer matrix
(Figure 4-1).

Figure 4-1: FT-IR spectra of Eudragit E PO (EPO), Carbamezapine (CBZ) and Caffeine
Citrate (CC).
More specifically, for the mixture of caffeine citrate (CC) and Eudragit E PO (EPO), CC
exhibits a very strong peak at 1642cm-1 while EPO presents only baseline contributions in this
same region. Overalys of the representative spectra can be seen in Figure 4-2 and Figure 4-3,
respectively.
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Figure 4-2: FT-IR spectral overlay of Eudragit E PO (EPO) and Caffeine Citrate (CC).
Here it can be seen that while a marginal contribution to the IR spectrum results from EPO
(approximately 0.02 AU) at 1642cm-1 the majority of the signal (approximately 0.28 AU) is from
CC, which allows this peak to be used for spectral imaging. Likewise for the combinations of
Carbamezapine (CBZ) and EPO, there is a clear contribution to the IR spectrum from CBZ at
1593cm-1 (approximately 0.22 AU) where EPO again presents only baseline contributions
(approximately 0.02 AU).
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Figure 4-3: FT-IR spectral overlay of Eudragit E PO (EPO) and Carbamezapine (CBZ).

Using these clear distinctions in the spectra allows for the generation of resolved chemical
images such as those in Figure 4-4. Here it can be seen that as the in-process melt travels along the
mixing block that the active (depicted as a function of intensity for the characteristic peak; 1642cm1

) is not being distributed thoughout the matrix as intensely as it is being dispersed into smaller

units within a given area, that is, the blue area that is representative of the absence of this peak is
slowly disappearing while the rea areas are declining in intensity. Interestingly, the corresponding
DSC thermograms for each of the three regions sampled showed practically no difference in AUC
as the in-process material passed through the mxing zone (1.23, 1.23 & 1.14 J/g, respectively)
indicating that though the material is being dispersed, it has not yet been converted from its
crystalline form to an amorphous form.
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Figure 4-4: IR chemical images take of CC from the Beginning, Middle and End of
Mixing zone.

The opposite can be determined from the behavior of CC in EPO when the mixing element angles
are chaged to 90o (Figure 4-5). Here we can see that the orientation of the mixing elements is
imparting more distributive character to the in-process material as the intensity of the signal from
CC is not as diminished as before, but is more distributed throughout the melt.
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Figure 4-5: IR chemical images take of CC from the Beginning, Middle and End of Mixing
zone.
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Figure 4-6: IR chemical images take of CBZ from the Beginning, Middle and End of
Mixing zone.
In Figure 4-6 it can be seen that CBZ is undergoing dispersive mxing similar to that of CC in
Figure 4-4. The DSC data supports this also as the AUC values are relatively unchanged (3.2, 3.0
& 2.6 J/g), again indicating that the dispersive mixing being imparted to the in-process material
is not yet sufficient to convert the crystalline lattice to its amorphous form.
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Figure 4-7: IR chemical images take of CBZ from the Beginning, Middle and End of
Mixing zone.
Figure 4-7 shows that CBZ is being distributed thoughout the matrix as would be expected from
perpendicular mixing elements; however, the DSC data indicates that that more material is
undergoing amorphous conversion due, in part, to the intense deformations imparted as the
polymer melt is divided and recombined (AUC 1.3, 0.68 and 0.68 J/g respectively). Despite the
conventional knowledge that perpendicular are primarily responsible for distributive mixing, it
would seem that the in-process material may respond differently due to its compositional
changes.
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4.5 Conclusion
FT-IR spectral imaging could be a useful offline tool for the investigation of the relationship
between screw configuration and API distribution/dispersion within a polymer matrix. It is worth
noting that only realtively simple missing blocks were examined in this study and far more
complex designs are commonly employed during a typical Hot-Melt Extrusion process. This in
combination with the effects noted here, namely the loss of crystallinity in the CBZ samples,
may indicate that particular formulations are more or less sensitive to the stresses imparted by
the process.
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CHAPTER 5.
SUMMARY & CONCLUSIONS
In chapter 2, the use of an extruded intermediate was investigated in a somewhat novel
sense (i.e. maintaining the API crystallinity) while approaching subsequent product development
from a more conventional prospective. Here it was noted that care must be taken to ensure the
physical identity of an API crystalline lattice. Additionally, incorporating milled extrudates into
oral solid dosage forms poses interesting challenges due to the large differences in density as
opposed to particle size. Chapter 3 explores the previously unreported use of a twin-screw extruder
for the production of a dry granulation using quality by design principles. This study, in tandem
with another study by a colleague, represents the first of its kind as no prior art could be found.
Here the use of a twin-screw extruder is explored as an alternative dry granulating technology.
Chapter 4 is an attempt to take a more granular look into the effects of screw design by examining
the effect of paddle offset angle on dispersion and distribution of two APIs within a polymer
matrix. This, in tandem with DSC data for phase identification, produced both anticipated (as in
the case of caffeine citrate) and unanticipated results (demonstrated by carbamezapine).
The underlying theme of the research performed in order to arrive at this dissertation is simple;
investigations into twin-screw extruder screw configuration. More broadly, this work investigates
the interplay between a formulation’s constituents and the extruder that is processing them. At the
time that this research was conducted, the current pharmaceutical literature concerning screwconfiguration seemed to regard it as more of an art rather than a science. On the other hand, the
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information available from food, metals, ceramics, engineering literature approached screw
geometry from a predominately mathematical perspective. In the current, neither of these
approaches work well. Until mathematical based simulation models are more fully matured, the
topic of screw configuration, and extrusion in general, should be treated with a combination of
theory and practical experience. Finally, while the melt extrusion process is completely amenable
to the FDA’s push toward the QbD paradigm shift, some understanding and flexibility will be
required on the agency’s end to fully realize this processing technology. More specifically, the
quantities listed in the Inactive Ingredient Database (IID) are simply insufficient to fully implement
this processing technology as a viable approach.
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